US6545028B2 - Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction - Google Patents

Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction Download PDF

Info

Publication number
US6545028B2
US6545028B2 US09/550,645 US55064500A US6545028B2 US 6545028 B2 US6545028 B2 US 6545028B2 US 55064500 A US55064500 A US 55064500A US 6545028 B2 US6545028 B2 US 6545028B2
Authority
US
United States
Prior art keywords
dihydro
dimethyl
pyridine
dicarboxylic acid
methyl ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US09/550,645
Other versions
US20020119989A1 (en
Inventor
Bo S. Jensen
Søren-Peter Olsen
Tino D. Jørgensen
Dorte Strøbæk
Palle Christophersen
Niels Ødum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aniona APS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Assigned to NEUROSEARCH A/S reassignment NEUROSEARCH A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ODUM, NIELS, JORGENSEN, TINO D., OLSEN, SOREN-PETER, CHRISTOPHERSEN, PALLE, STROBAEK, DORTE, JENSEN, BO S.
Assigned to NEUROSEARCH A/S reassignment NEUROSEARCH A/S CORRECTIVE ASSIGNMENT TO SECOND ASSIGNOR'S NAME AND ASSIGNEE'S ADDRESS CORRESPONDING TO THE ASSIGNMENT, PREVIOUSLY RECORDED AT REEL 010964, FRAME 0509. Assignors: ODUM, NIELS, JORGENSEN, TINO D., OLESEN, SOREN-PETER, CHRISTOPHERSEN, PALLE, STROBAEK, DORTE, JENSEN, BO S.
Publication of US20020119989A1 publication Critical patent/US20020119989A1/en
Assigned to POSEIDON PHARMACEUTICALS A/S reassignment POSEIDON PHARMACEUTICALS A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NEUROSEARCH A/S
Application granted granted Critical
Publication of US6545028B2 publication Critical patent/US6545028B2/en
Assigned to NEUROSEARCH A/S reassignment NEUROSEARCH A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: POSEIDON PHARMACEUTICALS A/S
Assigned to ANIONA APS reassignment ANIONA APS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NEUROSEARCH A/S
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to chemical compounds having inhibitory activity on an intermediate conductance Ca 2+ activated potassium channel (IK Ca ), and the use of such compounds for the treatment or alleviation of diseases or conditions relating to immune dysfunction.
  • IK Ca intermediate conductance Ca 2+ activated potassium channel
  • the invention relates to a method of screening a chemical compound for inhibitory activity on an intermediate conductance Ca 2+ activated potassium channel (IK Ca ).
  • Ion channels are transmembrane proteins, which catalyse the transport of inorganic ions across cell membranes.
  • the ion channels participate in processes as diverse as the generation and timing of action potentials, synaptic transmissions, secretion of hormones, contraction of muscles, etc.
  • anti-epileptic compounds like Phenytoin and Lamotrigine, which block voltage dependent Na + -channels in the brain
  • anti-hypertensive drugs like Nifedipine and Diltiazem
  • stimulators of insulin release like Glibenclamide and Tolbutamide, which block an ATP-regulated K + -channel in the pancreas.
  • Some of the currently used immunosuppressive compounds such as Cyclosporin A and FK506 prevent immunological proliferation by inhibition of the Ca 2+ /calmodulin-dependent Ser/Thr phosphatase calcineurin.
  • the usefulness of this class of compounds is limited by their side effects such as renal dysfunction, arterial hypertension, neurological effects (headache, insomnia, tremors, parasthesias, lethargy), gastrointestinal effects (nausea, vomiting, diarrhoea), and diabetes.
  • Another class of compounds comprising e.g. Azathioprine and Mizorbine interfere in a cytotoxic manner directly with the DNA-replication process.
  • cytotoxicity shows some selectivity towards strongly proliferating cells such as activated T- and B-lymphocytes, complications may follow due to effects on dividing cells in the entire body, including bone marrow, hair sacs, the skin, testis, ovary and epithelia such as the airways, the intestinal tract, and the thick ascending limp of the loop of Henle's.
  • a fairly new approach for suppression of immune responses is to interfere with ion channels in the plasma membrane of cells in the immune system, especially the T- and B-lymphocytes.
  • an initial signal in the switching from the resting phase to the proliferating phase is an activation of the phosphoinositide signalling pathway resulting in an increase in the intracellular concentration of Ca 2+ ([Ca 2+ ] i ) due to Ca 2+ release from intracellular stores.
  • a sustained elevated [Ca 2+ ]) i is maintained by an increased passive influx through mitogen regulated, voltage-independent Ca-channels. This increase in [Ca 2+ ] i is vital for the subsequent events leading to cell proliferation and secretion of lymphokines.
  • the [Ca 2+ ] is approximately 10 7 fold higher outside versus inside the cell, and the membrane potential is negative inside, i.e. there is an inwardly directed electrochemical Ca 2+ gradient.
  • the Ca-channels when activated they conduct Ca 2+ into the cell.
  • Ca 2+ influx via the Ca-channels tends to reduce or even eliminate this gradient, and thus to reduce the influx.
  • Concomitant opening of K-channels keeps the membrane potential negative, and activation of these channels is therefore essential for maintaining a large inwardly directed, electrochemical driving force for Ca 2+ .
  • K-channels have been described in B- and T-lymphocytes including both voltage-dependent K-channels (K v ), and voltage-independent Ca 2+ -activated K-channels (K Ca ). It is well established, that the K v -channels are activated by the Ca 2+ -induced depolarisation of the lymphocyte, and non-selective blockers of K v -channels are therefore quite effective immunosuppressive agents. However, these compounds in general have severe side effects due to block of repolarisation in excitable tissue (seizures, myotonic runs, high blood pressure, etc.).
  • a selective blocker of the K v 1.3-homomer might therefore be an ideal, relatively non-toxic, immunosuppressive agent.
  • Initial reports from these pharmacological programs indicate that selective K v 1.3-blockers are very effective as anti-inflammatory agents. However, the well-known toxicity of non-selective K v -blockers has apparently not disappeared.
  • An example is the potent K v 1.3 blocker CP-339,818.
  • This compound is also a potent blocker of K v 1.4, a cardiac and neuronal A-type K-channel. The side-effect of this compound is predicted to be interference with the cardiac action potential (long QT-syndrome toxicity) as well as with the action potential repolarisation and after hyperpolarization in neurons.
  • a hitherto untested alternative to the block of the voltage-dependent K-channels is a selective inhibition of the Ca 2+ -activated K-channels in T- and B- lymphocytes. These channels are directly activated by the increased [Ca 2+ ] i which is the primary signal for lymphocyte activation. Further, contrary to K v -channels, these channels are voltage-independent, and therefore they do not close upon hyperpolarization, implicating that they are even more effective than K v channels in maintaining a large inward driving force on Ca 2+ under conditions of elevated intercellular Ca 2+ -concentrations.
  • lymphocytes Two types of Ca 2+ -activated K-channels have been described from lymphocytes: 1) Small-conductance, apamin-sensitive, Ca 2+ -activated K-channels (SK Ca ) and 2) ⁇ Intermediate-conductance, inwardly rectifying, Clotrimazole-sensitive, Ca 2+ -activated K-channels (IK Ca ), also referred to as Gardos-channels. Resting T-lymphocytes express both SK Ca and IK Ca , whereas B-lymphocytes only express IK Ca .
  • IK Ca -channels Upon activation, prior to cell proliferation, the expression level of IK Ca increases approximately 30 fold in both T- and B-lymphocytes. The expression levels of both K v 1.3 and SK Ca remain unchanged, indicating a major role for the IK Ca -channel in induction of T- and B-cell proliferation. Contrary to the SK Ca -channels, which are extensively expressed in CNS and heart (measured as mRNA abundance by Northern hybridisation) and in PNS, skeletal muscle, hepatocytes (measured as functional channels by electrophysiology), expression of IK Ca -channels have never been reported from any excitable tissue.
  • blood cells such as erythrocytes, monocytes, lymphocytes, endothelial cells, and certain cell-lines with an epithelial ancestry, Ehrlich ascites tumor cells and HeLa cells appear to be the main source of this type of channels.
  • IK Ca -inhibitor Clotrimazole which is also a blocker of the cytochrome P-450 system
  • No toxicity related to K-channel blockade has been described.
  • the invention relates to the use of a chemical compound having IK Ca inhibitory activity for the manufacture of a medicament for the treatment or alleviation of diseases, disorders or. conditions relating to immune dysfunction.
  • the invention provides a pharmaceutical compositions for use in the treatment or alleviation of diseases, disorders or conditions relating to immune dysfunction, comprising an effective amount of a chemical compound having IK Ca inhibitory activity.
  • the invention provides a method of screening a chemical compound for inhibitory activity on an intermediate conductance Ca 2+ activated potassium channel (IK Ca ), which method comprises the steps of subjecting an IK Ca containing cell to the action of the chemical compound, and monitoring the membrane potential of the IK Ca containing cell.
  • IK Ca intermediate conductance Ca 2+ activated potassium channel
  • the present invention relates to the use of a chemical compound having IK Ca inhibitory activity for treatment or alleviation of diseases or conditions relating to immune dysfunction.
  • chemical compound having IK Ca inhibitory activity may be identified by its ability to inhibit hyperpolarization of an IK Ca containing cell, i.e. a cell containing an intermediate conductance Ca 2+ activated potassium channel (IK Ca ).
  • the chemical compounds having IK Ca inhibitory activity is identified by the method of screening described below.
  • Preferred chemical compounds having IK Ca inhibitory activity for use according to the invention are the derivatives of 1,4-dihydropyridine-3,5-dicarboxylic acid, the imidazole derivatives, the triazole derivatives, the nitroimidazole derivatives, and the derivatives and metabolites of Clotrimazole, described below.
  • the derivatives of 1,4-dihydropyridine-3,5-dicarboxylic acid have been disclosed in e.g. U.S. Pat. No. 3,799,934.
  • the imidazole derivatives, the triazole derivatives, and the nitroimidazole derivatives have been disclosed in e.g. U.S. Pat. No. 5,273,992.
  • the derivatives and metabolites of Clotrimazole have been disclosed in e.g. WO 96/08242.
  • the chemical compound having IK Ca inhibitory activity for use according to the invention is a symmetric or asymmetric derivative of 1,4-dihydropyridine-3,5-dicarboxylic acid represented by the general formula
  • R represents an alkyl group or a cycloalkyl group
  • R represents a mono- or polycyclic aryl group, which aryl group may be substituted one or more times with substituents selected from the grgroup consisting of halogen, trifluoromethyl (—CF 3 ), nitro (—NO 2 ), cyano (—CN), azido (—N 3 ), a group of the formula —S(O) n -alkyl, —S(O) n —NH-alkyl, or —S(O) n —N-(alkyl) 2 , in which n has a value of 0, 1 or 2, an alkyl group, a cycloalkyl group, an alkoxy group, a trifluoromethyl-oxy group (—OCF 3 ), a carboxy group (—COOH), a group of the formula —COO-alkyl, a carbamoyl group (—CONH 2 ), and a group of the formula —CONH-alkyl or —CON(alkyl) 2
  • R represents a mono- or poly-heterocyclic group, which heterocyclic group may be substituted one or more times with alkyl, alkoxy, a carboxy group (—COOH), a group of the formula —COO-alkyl, and/or a group of the formula —COO-phenyl;
  • R 1 , R 2 , R 3 and R 4 independent of each another, represents hydrogen, an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a phenyl group, a phenyl-alkyl group, a furanyl group, a furanyl-alkyl group, a pyridyl group, or a pyridyl-alkyl group;
  • the chemical compound for use according to the invention is a compound of the general formula (I) in which R represents a cyclohexyl group; or R represents a monosubstituted phenyl group, which phenyl group may be substituted one or more times with substituents selected from the group consisting of halogen, trifluoromethyl (—CF 3 ), nitro (—NO 2 ), and cyano (—CN); or R represents a pyridyl group or a dihydro-pyridyl group, which groups may be monosubstituted with a group of the formula —COO-alkyl, or a group of the formula—COO-phenyl.
  • R represents a cyclohexyl group
  • R represents a monosubstituted phenyl group, which phenyl group may be substituted one or more times with substituents selected from the group consisting of halogen, trifluoromethyl (—CF 3 ), nitro (—NO 2
  • the chemical compound for use according to the invention is a compound of the general formula (I) in which R represents a 2-nitrophenyl group, a 3-nitrophenyl group, a 4-nitrophenyl group, a 2-trifruoromethylphenyl group, a 3-trifruoromethylphenyl group, or a 4-trifruoromethylphenyl group; a 2-cyanophenyl group, a 3-cyanophenyl group, a 4-cyanophenyl group; or R represents a 2-pyridyl, a 3-pyridyl or a 4-pyridyl group, a 1,2-, 1,4- or 1,6-dihydro-2-pyridyl, a 1,2-, 1,4- or 1,6-dihydro-3-pyridyl, or a 1,2- or 1,4-dihydro-4-pyridyl group, which pyridyl or dihydropyridyl groups may be mono
  • the chemical compound for use according to the invention is a compound of the general formula (I) in which R 1 , R 2 , R 3 and R 4 , independent of each another, represents C 1-6 -alkyl, preferably methyl, ethyl, propyl, isopropyl, butyl, or isobutyl.
  • the chemical compound for use according to the invention is a compound of the general formula (I) which is an asymmetric derivative of the 1,4-dihydropyridine-3,5-dicarboxylic acid represented by the general formula (I).
  • Preferred asymmetric derivatives includes asymmetric C 1-6 -alkyl derivatives of the 1,4-dihydropyridine-3,5-dicarboxylic acid represented by the general formula (I).
  • Most preferred asymmetric compounds include
  • the chemical compound is a symmetric derivative of 1,4-dihydropyridine-3,5-dicarboxylic acid represented by the general formula (I).
  • Preferred chemical compounds include the symmetric C 1-6 -alkyl derivatives of the 1,4-dihydropyridine-3,5-dicarboxylic acid.
  • Most preferred symmetric chemical compounds for use-according to the invention include
  • the chemical compound having IK Ca inhibitory activity for use according to the invention is an imidazole derivative selected from the group consisting of
  • the chemical compound having IK Ca inhibitory activity for use according to the invention is a triazole derivative selected from the group consisting of
  • the chemical compound having IK Ca inhibitory activity for use according to the invention is a nitroimidazole derivative selected from the group consisting of
  • chemical compounds having IK Ca inhibitory activity for use according to the invention are derivatives and metabolites of Clotrimazole, as described in WO 96/08242.
  • X represents halogen, a trifluoromethyl group, a nitro group, or a cyano group
  • R represents hydrogen, halogen, hydroxy, an alkyl group, a cycloalkyl group, an alkoxy group, or an alkyloxy group;
  • R 1 represents hydrogen, or a phenyl group, which phenyl group may be substituted one or more times with substituents selected from the group consisting of halogen and hydroxy;
  • R 2 represents hydrogen, hydroxyl, alkyl, alkoxy
  • R 3 represents a group of the formula —Y—CH 2 —R 5 , wherein Y represents oxygen (—O—) or sulphur (—S—); a group of the formula ⁇ NO—CH 2 R 5 ; a group of the formula —O-phenyl—CH ⁇ CH 2 ; a group of the formula —CH 2 —CH(CH 3 )—S-phenyl, which phenyl may be substituted one or more times with substituents selected from the group consisting of halogen and hydroxy; or a phenyl group, which phenyl may be substituted one or more times with substituents selected from the group consisting of halogen and hydroxy; and wherein R 5 represents an ethenyl group (CH 2 ⁇ CH—); a phenyl group, which phenyl may be substituted one or more times with substituents selected from the group consisting of halogen and hydroxy; a phenyl-S-phenyl group, a group of the
  • Z represents S, O or N
  • R 6 represents hydrogen, halogen or hydroxy
  • Preferred derivatives and metabolites for use according to the invention include
  • halogen represents a fluorine, a chlorine, a bromine or a iodine atom.
  • an alkyl group designates a univalent saturated, straight or branched hydrocarbon chain.
  • the hydrocarbon chain preferably contain of from one to eighteen carbon atoms (C 1-8 -alkyl), more preferred of from one to six carbon atoms (C 1-6 -alkyl; lower alkyl), including pentyl, isopentyl, neopentyl, tertiary pentyl, hexyl and isohexyl.
  • alkyl represents a C 1-4 -alkyl group, including butyl, isobutyl, secondary butyl, and tertiary butyl.
  • alkyl represents a C 1-3 -alkyl group, which may in particular be methyl, ethyl, propyl or isopropyl.
  • a cycloalkyl group designates a cyclic alkyl group, preferably containing of from three to seven carbon atoms (C 3-7 -cycloalkyl), including cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • an alkenyl group designates a carbon chain containing one or more double bonds, including di-enes, tri-enes and poly-enes.
  • the alkenyl group of the invention comprises of from two to six carbon atoms (C 2-6 -alkenyl), including at least one double bond.
  • the alkenyl group of the invention is ethenyl; 1,2- or 2,3-propenyl; or 1,2-, 2,3-, or 3,4-butenyl.
  • an alkynyl group designates a carbon chain containing one or more triple bonds, including di-ynes, tri-ynes and poly-ynes.
  • the alkynyl group of the invention comprises of from two to six carbon atoms (C 2-6 -alkynyl), including at least one triple bond.
  • the alkynyl group of the invention is ethynyl, 1,2- or 2,3-propynyl, 1,2-, 2,3- or 3,4-butynyl.
  • alkoxy group designates an “alkyl-O—” group, wherein alkyl is as defined above.
  • a mono- or polycyclic aryl group designates a monocyclic or polycyclic aromatic hydrocarbon group.
  • preferred aryl groups of the invention are phenyl, naphthyl and anthracenyl.
  • a mono- or poly-heterocyclic group is a mono- or polycyclic aromatic group, which holds one or more heteroatoms in its ring structure.
  • Preferred heterocyclic monocyclic groups of the invention are 5- and 6 membered heterocyclic monocyclic groups.
  • heterocyclic monocyclic groups of the invention include furanyl, imidazolyl, isoimidazolyl, 2-isoimidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, thiadiazolyl, thiazolyl, and thienyl.
  • preferred heterocyclic polycyclic groups of the invention include benzimidazolyl, indolyl, isoquinolyl and quinolyl.
  • the chemical compound of the invention may be provided in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, or pre- or prodrug forms of the chemical compound of the invention.
  • Examples of pharmaceutically acceptable addition salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the acetate derived from acetic acid, the aconate derived from aconitic acid, the ascorbate derived from ascorbic acid, the benzenesulfonate derived from benzensulfonic acid, the benzoate derived from benzoic acid, the cinnamate derived from cinnamic acid, the citrate derived from citric acid, the embonate derived from embonic acid, the enantate derived from enanthic acid, the formate derived from formic acid, the fumarate derived from fumaric acid, the glutamate derived from glutamic acid, the glycolate derived from glycolic acid, the hydrochloride derived from hydrochloric acid, the hydrobromide derived from hydrobromic acid, the lactate derived from lactic acid, the maleate derived from maleic acid, the malonate derived from mal
  • acids such as oxalic acid, which may not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining a chemical compound of the invention and its pharmaceutically acceptable acid addition salt.
  • Metal salts of a chemical compound of the invention includes alkali metal salts, such as the sodium salt, of a chemical compound of the invention containing a carboxy group.
  • the chemical compound of the invention may be provided in dissoluble or indissoluble forms together with a pharmaceutically acceptable solvents such as water, ethanol, and the like.
  • Dissoluble forms may also include hydrated forms such as the monohydrate, the dihydrate, the hemihydrate, the trihydrate, the tetrahydrate, and the like. In general, the dissoluble forms are considered equivalent to indissoluble forms for the purposes of this invention.
  • the chemical compounds of the present invention may exist in (+) and ( ⁇ ) forms as well as in racemic forms.
  • the racemates of these isomers and the individual isomers themselves are within the scope of the present invention.
  • Racemic forms can be resolved into the optical antipodes by known methods and techniques.
  • One way of separating the diastereomeric salts is by use of an optically active acid, and liberating the optically active amine compound by treatment with a base.
  • Another method for resolving racemates into the optical antipodes is based upon chromatography on an optical active matrix.
  • Racemic compounds of the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallisation of d- or I- (tartrates, mandelates, or camphorsulphonate) salts for example.
  • the chemical compounds of the present invention may also be resolved by the formation of diastereomeric amides by reaction of the chemical compounds of the present invention with an optically active activated carboxylic acid such as that derived from (+) or ( ⁇ ) phenylalanine, (+) or ( ⁇ ) phenylglycine, (+) or ( ⁇ ) camphanic acid or by the formation of diastereomeric carbamates by reaction of the chemical compound of the present invention with an optically active chloroformate or the like.
  • an optically active activated carboxylic acid such as that derived from (+) or ( ⁇ ) phenylalanine, (+) or ( ⁇ ) phenylglycine, (+) or ( ⁇ ) camphanic acid
  • some of the chemical compounds of the invention being oximes, may thus exist in two forms, syn- and anti-form (Z- and E-form), depending on the arrangement of the substituents around the —C ⁇ N— double bond.
  • a chemical compound of the present invention may thus be the syn- or the anti-form (Z- and E-form), or it may be a mixture hereof.
  • the present invention provides a method for the screening of chemical compounds for inhibitory activity on an intermediate conductance Ca 2+ activated potassium channel (IK Ca ), by which method a chemical compound having IK Ca inhibitory activity is identified by its ability to inhibit hyperpolarization of the cell.
  • IK Ca intermediate conductance Ca 2+ activated potassium channel
  • the screening method of the invention comprises the steps of
  • step (ii) More particularly the monitoring of the membrane potential of the IK Ca containing cell of step (ii) is carried out in order to monitor changes in the membrane potential caused by the action of the chemical compound.
  • the IK Ca used in the method of the invention may be of any origin, however, preferably of human or animal origin. Also, the IK Ca may be endogenous or it may be exogenous to the cell in question.
  • the IK Ca of the IK Ca containing cell is an ion channel that is endogenous to the cell in question, and which cell may in particular be a T- or B-lymphocyte or other cells known to express IK Ca , e.g. a HeLa cell, or a cell of epithelial origin, a cell of endothelial origin, or a blood cell.
  • the IK Ca of the IK Ca containing cell is an ion channel that is exogenous to the cell in question, and which cell may in particular be a human embryonic kidney (HEK) cell, a HEK 293 cell, a Chinese hamster ovary (CHO) cell, a Xenopus laevis oocyte (XLO) cell, or any other cell line able to express IK Ca .
  • HEK human embryonic kidney
  • HEK 293 a Chinese hamster ovary
  • CHO Chinese hamster ovary
  • XLO Xenopus laevis oocyte
  • the IK Ca preferably is of human origin.
  • the IK Ca may be isolated from salivary glands, from lung tissue, from tracheal tissue, from placenta tissue, from pancreas tissue, from lymphocytes, from colon tissue, from kidney tissue, from thymus tissue, from bone marrow, from prostate tissue, from stomach tissue, from liver tissue, from foetal liver tissue, from mammary glands, from small intestine tissue, from spleen tissue, or from lymph node tissue.
  • the IK Ca may be isolated from salivary glands, from lung tissue, from tracheal tissue, from placenta tissue, from pancreas tissue, or from lymphocytes.
  • the IK Ca is encoded by the DNA sequence presented as SEQ ID NO: 1, or a homologous sequence, e.g. a DNA sequence showing a homology to SEQ ID NO: 1 of at least 80%, more preferred at least 90%, most preferred at least 95%.
  • the membrane potential is monitored in order to determine changes in the membrane potential.
  • the membrane potential may be monitored using established methods.
  • monitoring of the membrane potential of the IK Ca containing cell is performed by patch clamp techniques, e.g. as described by Hamill, O. P., et al., Pflügers Arch. 1981 351 85-100.
  • monitoring of the membrane potential of the IK Ca containing cell is performed by the automatic patch clamp method described in pending patent application DK 1151/97.
  • monitoring of the membrane potential of the IK Ca containing cell is performed using fluorescence methods.
  • the IK Ca containing cell is mixed with a membrane potential indicating agent, that allow for a determination of changes in the membrane potential of the cell, caused by the addition of the test compound.
  • the membrane potential indicating agent employed in the method of the invention may be any agent that allow monitoring of changes in the membrane potential.
  • the membrane potential indicating agent is a fluorescent indicator.
  • the fluorescent indicator must be sufficiently sensitive so as to produce a detectable change in fluorescence intensity in the presence of calcium ions.
  • Preferred fluorescent indicators are in particular DIBAC 4 (3), DiOC5(3), and DIOC2(3).
  • Monitoring of the membrane potential of the IK Ca containing cell may then be performed by spectroscopic methods, e.g. using a FLIPR assay (Fluorescence Image Plate Reader; available from Molecular Devices), or by using the automated analysis equipment described in U.S, Pat. No. 5,670,113.
  • FLIPR assay Fluorescence Image Plate Reader
  • the invention relates to an encompasses the chemical compounds identified by the method of the invention and their use the use of these compounds for the treatment or alleviation of diseases or conditions relating to immune dysfunction.
  • the IK Ca inhibitory compounds of the invention are useful as immune modulating agents, i.e. agents capable of regulating the immune system. More particularly, the IK Ca inhibitory compounds of the present invention may be used for reducing or inhibiting undesired immunoregulatory actions.
  • the invention relates to the use of an IK Ca inhibitory compound for the treatment or alleviation of a diseases, disorders or condition related to immune dysfunction.
  • Conditions which may benefit from this treatment include, but are not limited to diseases, disorders or conditions such as autoimmune diseases, e.g. Addison's disease, alopecia areata, Ankylosing spondylitis, hemolytic anemia (anemia haemolytica), pernicious anemia (anemia perniciosa), aphthae, aphthous stomatitis, arthritis, osteoarthritis, rheumatoid arthritis, aspermiogenese, asthma bronchiale, autoimmune asthma, autoimmune hemolysis, Bechet's disease, Boeck's disease, inflammatory bowel disease, Burkitt's lymphoma, Chron's disease, chorioiditis, colitis ulcerosa, Coeliac disease, cryoglobulinemia, dermatitis herpetiformis, dermatomyositis, insulin-dependent type I diabetes, juvenile diabetes, idiopathic diabetes insipidus, insulin-dependent diabetes
  • the invention relates to a chemical compound having IK Ca inhibitory activity for use as a medicament.
  • the invention relates to the use of a chemical compound having IK Ca inhibitory activity for use in the manufacture of a medicament for the treatment of treatment of diseases related to immune dysfunction.
  • the medicament is an immune system suppressing medicament (an immunosuppressivum).
  • the invention relates to pharmaceutical compositions for use in the treatment or alleviation of diseases, disorders or conditions related to immune dysfunction, which pharmaceutical composition comprises a therapeutically effective amount of a chemical compound having IK Ca inhibitory activity, as identified by the method of the invention.
  • a chemical compound of the invention for use in therapy may be administered in the form of the raw chemical compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.
  • the invention provides pharmaceutical compositions comprising the chemical compound of the invention or a pharmaceutically acceptable salt or derivative thereof together with one or more pharmaceutically acceptable carriers therefor and, optionally, other therapeutic and/or prophylactic ingredients.
  • the carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • the pharmaceutical composition of the invention may be administered by any convenient route which suite the desired therapy.
  • Preferred routes of administration include oral administration, in particular in tablet, in capsule, in dragé, in powder, or in liquid form, and parenteral administration, in particular cutaneous, subcutaneous, intramuscular, or intravenous injection.
  • the pharmaceutical composition may be prepared by the skilled person using standard and conventional techniques appropriate to the desired formulation. When desired, compositions adapted to give sustained release of the active ingredient may be employed.
  • compositions containing of from about 0.1 to about 500 mg of active ingredient per individual dose, preferably of from about 1 to about 100 mg, most preferred of from about 1 to about 10 mg, are suitable for therapeutic treatments.
  • the active ingredient may be administered in one or several doses per day.
  • a satisfactory result can, in certain instances, be obtained at a dosage as low as 0.1 ⁇ g/kg i.v. and 1 ⁇ g/kg p.o.
  • the upper limit of the dosage range is presently considered to be about 10 mg/kg i.v. and 100 mg/kg p.o.
  • Preferred ranges are from about 0.1 ⁇ g/kg to about 10 mg/kg i.v., and from about 1 ⁇ g/kg to about 100 mg/kg p.o.
  • the pharmaceutical composition of the invention comprises a chemical compound which is an imidazole derivative, in particular Clotrimazole, Miconazole, Ketonazole, Econazole, Butoconazole, Oxiconazole, Sulconazole, or Tioconazole.
  • a chemical compound which is an imidazole derivative in particular Clotrimazole, Miconazole, Ketonazole, Econazole, Butoconazole, Oxiconazole, Sulconazole, or Tioconazole.
  • the pharmaceutical composition of the invention comprises a chemical compound which is a nitroimidazole derivative, in particular Metronidazole, Tinidazole, Nimorazole, Ornidazole, or Benznidazole.
  • the pharmaceutical composition of the invention comprises a chemical compound which is a triazole derivative, in particular Fluconazole, Tercolazole, or Itraconazole.
  • the pharmaceutical composition of the invention comprises a chemical compound which is a metabolite of Clotrimazole, in particular 2-chlorophenyl-4-hydroxy-phenyl-phenyl-methane, 2-chlorophenyl-bis-phenyl-methane, or 2-chlorophenyl-bis-phenyl-methanol.
  • the IK Ca inhibitory compounds of the invention are useful as immune modulating agents, i.e. agents capable of regulating the immune system, and may be used in a method of for reducing or inhibiting undesired immunoregulatory actions.
  • the invention relates to a method of treatment or alleviation of diseases, disorders or conditions relating to immune dysfunction in a living body, said method comprising administering to said living body an effective amount of a chemical compound having IK Ca inhibitory activity.
  • the full length coding sequence of a cDNA encoding human placenta Ca 2+ -activated, intermediate conductance potassium channel protein (SEQ ID NO: 2) is radio labelled by random priming and used as a hybridisation probe to screen a human placenta cDNA library under hybridisation. conditions of 1 M NaCl, 1% SDS and 50% formamide at 42° C. Hybridisation wash conditions are 55° C., 0.2 ⁇ SSC and 0.1% SDS. Positively hybridising clones are purified and the nucleotide and predicted amino acid sequence are determined.
  • DNA encoding human placenta Ca 2+ -activated, intermediate conductance potassium channel protein was determined by transfecting mammalian cells with a cDNA preparation and using the membrane patch clamp technique [Hamill, O. P., et al., Pflügers Arch. 1981 351 85-100] or using the Fluorescence Image Plate Reader (FLIPR) assay.
  • a cDNA encoding the human placenta Ca 2+ -activated, intermediate conductance potassium channel protein was identified by a BLAST search of the expressed sequence tag (EST) database using the query sequence (51 Amino acids):
  • a BLAST search retrieved the GenBank Entry No. N56819, a cDNA encoding the entire Ca 2+ -activated, intermediate conductance potassium channel protein.
  • HEK293 or CHO tissue culture cells were grown in DMEM (Dulbecco's Modified Eagle Medium) supplemented with 10% FCS (foetal calf serum) at 37° C. in 5% CO 2 .
  • DMEM Dulbecco's Modified Eagle Medium
  • FCS calcium calf serum
  • Cells prepared for the electrophysiological screening were transfected with pNS2Z_hIK2, which besides coding for the human placenta Ca 2+ -activated intermediate conductance potassium channel protein also codes for the green fluorescent protein EGFP.
  • Cells prepared for the FLIPR assay were transfected with pNS1Z_hIK2, which is an analogue to pNS2Z_hIK2 but without the cDNA encoding EGFP. The lipofection mixture was overlaid on the cells and incubated at 37° C. for 5 hours. The cells were then rinsed with regular media and plated either to 30 mm culture dishes (eletrophysiological assay) or to 96-well microtiter plates (FLIPR assay).
  • Transfected HEK293 cells were assayed for the presence of Ca 2+ -activated, intermediate conductance potassium channel protein by a fluometric technique based on the membrane potential sensitive dye DIBAC 4 (3). After transfection, cells were washed twice with a 5 ⁇ M DIBAC 4 (3)/FLIPR buffer solution (100 ⁇ l in each well).
  • the FLIPR buffer solution contained in mM: 145 NaCl, 1 KCl, 1 CaCl 2 , 1 MgCl 2 , 10 HEPES, 10 glucose and with pH adjusted to 7.4.
  • DIBAC 4 (3)/FLIPR buffer solution was added to each well and the microtiter plate was equilibrated at 35° C. for 20-30 min.
  • a drugplate containing lonomycin and Thapsigargin was made 10 ⁇ concentrated and was also equilibrated at 35° C. before starting the experiment.
  • the FLIPR was programmed to do a sample reading every 20 sec. for a total period of 10 min.
  • the assay was started with a pre-run for 1 min, followed by a simultaneous addition of 20 ⁇ l “drug” to all 96 wells.
  • Addition of lonomycin and Thapsigargin both result in an increase in the intracellular Ca 2+ concentration, which in turn activated the intermediate conductance potassium channels. This activation was observed as a decrease in the fluorescent signal which correlates to a membrane hyperpolarization.
  • HEK293 or CHO tissue culture cells were grown in DMEM (Dulbecco's Modified Eagle Medium) supplemented with 10% FCS (foetal calf serum) at 37° C. in 5% CO 2 .
  • DMEM Dulbecco's Modified Eagle Medium
  • FCS calcium calf serum
  • the cells were then rinsed with regular media and plated to a 30 mm culture dish. 18-48 hours after, transfected cells were assayed for the presence of Ca 2+ -activated, intermediate conductance potassium channel protein by electrophysiological measurements.
  • DNA encoding human placenta Ca 2+ -activated, intermediate conductance potassium channel protein was determined by transfecting mammalian cells with a cDNA preparation and by using the patch clamp technique (see Hamill O P et al., Pflüagers Arch. 1981 351 85-100).
  • Clotrimazole sensitivity of the expressed channels was determined by addition of 1 ⁇ M Clotrimazole to the bath solution.
  • Application of Clotrimazole resulted in an inhibition of the Ca 2+ -activated potassium current which was reversed by washout of Clotrimazole from the bath solution.
  • the chemical compounds used according to the invention prevent immunological proliferation by selective inhibition of the Ca 2+ -activated K-channels in T- and B-lymphocytes. This effect may be verified using various proliferation assays.
  • the proliferative assay described by ⁇ dum et al. [ ⁇ dum N, Kanner S B, Ledbetter J A, & Svejgaard A; J. Immunol. 1993 150 (12) 5289-5298] was used.
  • the chemical compounds representative of the invention tested in this experiment are Nitrendipine, a derivative of the 1,4-dihydropyridine-3,5-dicarboxylic acid, and the imidazole derivative Clotrimazole.
  • Assays were performed in culture medium (RPMI 1640; available from Gibco, Grand island, N.Y.) supplemented with 10% pooled human serum, 2 mM L-glutamine, 100 ⁇ g/ml penicillin, and 100 ⁇ g/ml streptomycin (available from Novo Nordisk, Copenhagen, Denmark) in 96-well round bottom tissue culture plates (available from Nunc, Roskilde, Denmark) with a final volume of 200 ⁇ l.
  • T cells were preincubated for three hours with the test compounds before addition of antigen (crude Candida albicans extract, 10 ⁇ g/ml). T cells were cultured at 5 ⁇ 10 4 cells/well for 144 hours. Twelve hours before harvest, [ 3 H]thymidine (1 ⁇ Ci/well) was added. The cells were harvested onto glass fibre filters, and the [ 3 H]thymidine incorporation was measured in a scintillation counter. The results were expressed as mean counts per minute (cpm) from triplicate cultures.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to treatment or alleviation of a disease, condition or disorder selected from inflammatory bowel disease, Chron's disease, colitis ulcerosa, Coeliac disease, dermatitis herpetiformis, dermatomyositis, enteritis allergia, erytherma nodosum leprosum, ileitis regionalis, psoriasis, purpura, scleritis or scleroderma by administering to a living body certain imidazole, triazole, or 1,4-dihydropyridine derivatives.

Description

This application is a continuation of PCT/DK98/00490, filed Nov. 13, 1998.
TECHNICAL FIELD
The present invention relates to chemical compounds having inhibitory activity on an intermediate conductance Ca2+ activated potassium channel (IKCa), and the use of such compounds for the treatment or alleviation of diseases or conditions relating to immune dysfunction.
Moreover, the invention relates to a method of screening a chemical compound for inhibitory activity on an intermediate conductance Ca2+ activated potassium channel (IKCa).
BACKGROUND ART
Ion channels are transmembrane proteins, which catalyse the transport of inorganic ions across cell membranes. The ion channels participate in processes as diverse as the generation and timing of action potentials, synaptic transmissions, secretion of hormones, contraction of muscles, etc.
Many drugs exert their effects via modulation of ion channels. Examples are anti-epileptic compounds like Phenytoin and Lamotrigine, which block voltage dependent Na+-channels in the brain, anti-hypertensive drugs like Nifedipine and Diltiazem, which block voltage dependent Ca2+-channels in smooth muscle cells, and stimulators of insulin release like Glibenclamide and Tolbutamide, which block an ATP-regulated K+-channel in the pancreas.
There is a large and still growing demand for non-toxic immunoregulating agents for use in relation to e.g. organ transplantation and auto-immune diseases.
Some of the currently used immunosuppressive compounds such as Cyclosporin A and FK506 prevent immunological proliferation by inhibition of the Ca2+/calmodulin-dependent Ser/Thr phosphatase calcineurin. The usefulness of this class of compounds is limited by their side effects such as renal dysfunction, arterial hypertension, neurological effects (headache, insomnia, tremors, parasthesias, lethargy), gastrointestinal effects (nausea, vomiting, diarrhoea), and diabetes.
Another class of compounds comprising e.g. Azathioprine and Mizorbine interfere in a cytotoxic manner directly with the DNA-replication process. Although cytotoxicity shows some selectivity towards strongly proliferating cells such as activated T- and B-lymphocytes, complications may follow due to effects on dividing cells in the entire body, including bone marrow, hair sacs, the skin, testis, ovary and epithelia such as the airways, the intestinal tract, and the thick ascending limp of the loop of Henle's.
A fairly new approach for suppression of immune responses is to interfere with ion channels in the plasma membrane of cells in the immune system, especially the T- and B-lymphocytes. Upon exposure to antigens by antigen presenting macrophages or to mitogens such as IL-2 or IFN-γ, an initial signal in the switching from the resting phase to the proliferating phase is an activation of the phosphoinositide signalling pathway resulting in an increase in the intracellular concentration of Ca2+ ([Ca2+]i) due to Ca2+ release from intracellular stores. A sustained elevated [Ca2+])i is maintained by an increased passive influx through mitogen regulated, voltage-independent Ca-channels. This increase in [Ca2+]i is vital for the subsequent events leading to cell proliferation and secretion of lymphokines.
In resting T- and B-lymphocytes, the [Ca2+] is approximately 107 fold higher outside versus inside the cell, and the membrane potential is negative inside, i.e. there is an inwardly directed electrochemical Ca2+ gradient. Thus, when the Ca-channels are activated they conduct Ca2+ into the cell. However, Ca2+ influx via the Ca-channels, tends to reduce or even eliminate this gradient, and thus to reduce the influx. Concomitant opening of K-channels keeps the membrane potential negative, and activation of these channels is therefore essential for maintaining a large inwardly directed, electrochemical driving force for Ca2+.
In the presence of blockers of lymphocyte K-channels, the cells depolarise, and thereby the Ca2+ influx necessary for the activation of the immune response is reduced.
Several types of K-channels have been described in B- and T-lymphocytes including both voltage-dependent K-channels (Kv), and voltage-independent Ca2+-activated K-channels (KCa). It is well established, that the Kv-channels are activated by the Ca2+-induced depolarisation of the lymphocyte, and non-selective blockers of Kv-channels are therefore quite effective immunosuppressive agents. However, these compounds in general have severe side effects due to block of repolarisation in excitable tissue (seizures, myotonic runs, high blood pressure, etc.).
Considerable effort has been made into the development of immunoselective Kv-blockers. The molecular rationale for this, has been the observation that T-lymphocytes express homomeric Kv1.3-channels in contrast to excitable cells, which always express several heteromeric subtypes of the Kv-channels.
A selective blocker of the Kv1.3-homomer might therefore be an ideal, relatively non-toxic, immunosuppressive agent. Initial reports from these pharmacological programs indicate that selective Kv1.3-blockers are very effective as anti-inflammatory agents. However, the well-known toxicity of non-selective Kv-blockers has apparently not disappeared. An example is the potent Kv1.3 blocker CP-339,818. This compound is also a potent blocker of Kv1.4, a cardiac and neuronal A-type K-channel. The side-effect of this compound is predicted to be interference with the cardiac action potential (long QT-syndrome toxicity) as well as with the action potential repolarisation and after hyperpolarization in neurons.
SUMMARY OF THE INVENTION
A hitherto untested alternative to the block of the voltage-dependent K-channels is a selective inhibition of the Ca2+-activated K-channels in T- and B- lymphocytes. These channels are directly activated by the increased [Ca2+]i which is the primary signal for lymphocyte activation. Further, contrary to Kv-channels, these channels are voltage-independent, and therefore they do not close upon hyperpolarization, implicating that they are even more effective than Kv channels in maintaining a large inward driving force on Ca2+ under conditions of elevated intercellular Ca2+-concentrations.
Two types of Ca2+-activated K-channels have been described from lymphocytes: 1) Small-conductance, apamin-sensitive, Ca2+-activated K-channels (SKCa) and 2)− Intermediate-conductance, inwardly rectifying, Clotrimazole-sensitive, Ca2+-activated K-channels (IKCa), also referred to as Gardos-channels. Resting T-lymphocytes express both SKCa and IKCa, whereas B-lymphocytes only express IKCa.
Upon activation, prior to cell proliferation, the expression level of IKCa increases approximately 30 fold in both T- and B-lymphocytes. The expression levels of both Kv1.3 and SKCa remain unchanged, indicating a major role for the IKCa-channel in induction of T- and B-cell proliferation. Contrary to the SKCa-channels, which are extensively expressed in CNS and heart (measured as mRNA abundance by Northern hybridisation) and in PNS, skeletal muscle, hepatocytes (measured as functional channels by electrophysiology), expression of IKCa-channels have never been reported from any excitable tissue. In fact, blood cells such as erythrocytes, monocytes, lymphocytes, endothelial cells, and certain cell-lines with an epithelial ancestry, Ehrlich ascites tumor cells and HeLa cells appear to be the main source of this type of channels.
Furthermore, the very recent cloning of IKCa has enabled the demonstration of the mRNA for this gene in several organs including placenta, salivary glands, lung and pancreas. Thus, specific blockers of IKCa are likely to be very effective as immunosuppressive agents, and devoid of side effects on excitable tissue. In fact, the IKCa-inhibitor Clotrimazole (which is also a blocker of the cytochrome P-450 system) has been extensively used clinically in the systemic treatment of fungal infections. No toxicity related to K-channel blockade has been described.
Accordingly, in its first aspect, the invention relates to the use of a chemical compound having IKCa inhibitory activity for the manufacture of a medicament for the treatment or alleviation of diseases, disorders or. conditions relating to immune dysfunction.
In another aspect the invention provides a pharmaceutical compositions for use in the treatment or alleviation of diseases, disorders or conditions relating to immune dysfunction, comprising an effective amount of a chemical compound having IKCa inhibitory activity.
In yet another aspect the invention provides a method of screening a chemical compound for inhibitory activity on an intermediate conductance Ca2+ activated potassium channel (IKCa), which method comprises the steps of subjecting an IKCa containing cell to the action of the chemical compound, and monitoring the membrane potential of the IKCa containing cell.
DETAILED DISCLOSURE OF THE INVENTION
The present invention relates to the use of a chemical compound having IKCa inhibitory activity for treatment or alleviation of diseases or conditions relating to immune dysfunction.
Chemical Compound having IKCa Inhibitory Activity
According to the invention, chemical compound having IKCa inhibitory activity may be identified by its ability to inhibit hyperpolarization of an IKCa containing cell, i.e. a cell containing an intermediate conductance Ca2+activated potassium channel (IKCa). In a preferred embodiment, the chemical compounds having IKCa inhibitory activity is identified by the method of screening described below.
Preferred chemical compounds having IKCa inhibitory activity for use according to the invention are the derivatives of 1,4-dihydropyridine-3,5-dicarboxylic acid, the imidazole derivatives, the triazole derivatives, the nitroimidazole derivatives, and the derivatives and metabolites of Clotrimazole, described below. The derivatives of 1,4-dihydropyridine-3,5-dicarboxylic acid have been disclosed in e.g. U.S. Pat. No. 3,799,934. The imidazole derivatives, the triazole derivatives, and the nitroimidazole derivatives have been disclosed in e.g. U.S. Pat. No. 5,273,992. The derivatives and metabolites of Clotrimazole have been disclosed in e.g. WO 96/08242.
Derivatives of 1,4-dihydropyridine-3,5-dicarboxylic acid
In a preferred embodiment, the chemical compound having IKCa inhibitory activity for use according to the invention is a symmetric or asymmetric derivative of 1,4-dihydropyridine-3,5-dicarboxylic acid represented by the general formula
Figure US06545028-20030408-C00001
wherein
R represents an alkyl group or a cycloalkyl group;
or R represents a mono- or polycyclic aryl group, which aryl group may be substituted one or more times with substituents selected from the grgroup consisting of halogen, trifluoromethyl (—CF3), nitro (—NO2), cyano (—CN), azido (—N3), a group of the formula —S(O)n-alkyl, —S(O)n—NH-alkyl, or —S(O)n—N-(alkyl)2, in which n has a value of 0, 1 or 2, an alkyl group, a cycloalkyl group, an alkoxy group, a trifluoromethyl-oxy group (—OCF3), a carboxy group (—COOH), a group of the formula —COO-alkyl, a carbamoyl group (—CONH2), and a group of the formula —CONH-alkyl or —CON(alkyl)2;
or R represents a mono- or poly-heterocyclic group, which heterocyclic group may be substituted one or more times with alkyl, alkoxy, a carboxy group (—COOH), a group of the formula —COO-alkyl, and/or a group of the formula —COO-phenyl;
and R1, R2, R3 and R4, independent of each another, represents hydrogen, an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a phenyl group, a phenyl-alkyl group, a furanyl group, a furanyl-alkyl group, a pyridyl group, or a pyridyl-alkyl group;
or a pharmaceutically acceptable acid addition salt thereof.
In a more preferred embodiment, the chemical compound for use according to the invention is a compound of the general formula (I) in which R represents a cyclohexyl group; or R represents a monosubstituted phenyl group, which phenyl group may be substituted one or more times with substituents selected from the group consisting of halogen, trifluoromethyl (—CF3), nitro (—NO2), and cyano (—CN); or R represents a pyridyl group or a dihydro-pyridyl group, which groups may be monosubstituted with a group of the formula —COO-alkyl, or a group of the formula—COO-phenyl.
In a another preferred embodiment, the chemical compound for use according to the invention is a compound of the general formula (I) in which R represents a 2-nitrophenyl group, a 3-nitrophenyl group, a 4-nitrophenyl group, a 2-trifruoromethylphenyl group, a 3-trifruoromethylphenyl group, or a 4-trifruoromethylphenyl group; a 2-cyanophenyl group, a 3-cyanophenyl group, a 4-cyanophenyl group; or R represents a 2-pyridyl, a 3-pyridyl or a 4-pyridyl group, a 1,2-, 1,4- or 1,6-dihydro-2-pyridyl, a 1,2-, 1,4- or 1,6-dihydro-3-pyridyl, or a 1,2- or 1,4-dihydro-4-pyridyl group, which pyridyl or dihydropyridyl groups may be monosubstituted with C1-6-alkyl, a group of the formula —COO—C1-6-alkyl, or a group of the formula —COO-phenyl.
In yet another preferred embodiment, the chemical compound for use according to the invention is a compound of the general formula (I) in which R1, R2, R3 and R4, independent of each another, represents C1-6-alkyl, preferably methyl, ethyl, propyl, isopropyl, butyl, or isobutyl.
In a more preferred embodiment, the chemical compound for use according to the invention is a compound of the general formula (I) which is an asymmetric derivative of the 1,4-dihydropyridine-3,5-dicarboxylic acid represented by the general formula (I). Preferred asymmetric derivatives includes asymmetric C1-6-alkyl derivatives of the 1,4-dihydropyridine-3,5-dicarboxylic acid represented by the general formula (I). Most preferred asymmetric compounds include
1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5-dicarboxylic acid ethyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5-dicarboxylic acid propyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5-dicarboxylic acid isopropyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylic acid ethyl methyl ester (Nitrendipine);
1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylic acid propyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylic acid isopropyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)pyridine-3,5-dicarboxylic acid ethyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)pyridine-3,5-dicarboxylic acid propyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)pyridine-3,5-dicarboxylic acid isopropyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-trifluorophenyl)pyrdine-3,5-dicarboxylic acid ethyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-trifluorophenyl)pyridine-3,5-dicarboxylic acid propyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-trifluorophenyl)pyridine-3,5-dicarboxylic acid isopropyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-trifluorophenyl)pyridine-3,5-dicarboxylic acid ethyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-trifluorophenyl)pyridine-3,5-dicarboxylic acid propyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-trifluorophenyl)pyridine-3,5-dicarboxylic acid isopropyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-trifluorophenyl)pyridine-3,5-dicarboxylic acid ethyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-trifluorophenyl)pyridine-3,5-dicarboxylic acid propyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-trifluorophenyl)pyridine-3,5-dicarboxylic acid isopropyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-cyanophenyl)pyridine-3,5-dicarboxylic acid ethyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-cyanophenyl)pyridine-3,5-dicarboxylic acid propyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-cyanophenyl)pyridine-3,5-dicarboxylic acid isopropyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-cyanophenyl)pyridine-3,5-dicarboxylic acid ethyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-cyanophenyl)pyridine-3,5-dicarboxylic acid propyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-cyanophenyl)pyridine-3,5-dicarboxylic acid isopropyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-cyanophenyl)pyridine-3,5-dicarboxylic acid ethyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-cyanophenyl)pyridine-3,5-dicarboxylic acid propyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-cyanophenyl)pyridine-3,5-dicarboxylic acid isopropyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-pyridyl)pyridine-3,5-dicarboxylic acid ethyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-pyridyl)pyridine-3,5-dicarboxylic acid propyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-pyridyl)pyridine-3,5-dicarboxylic acid isopropyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-pyridyl)pyridine-3,5-dicarboxylic acid ethyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-pyridyl)pyridine-3,5-dicarboxylic acid propyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-pyridyl)pyridine-3,5-dicarboxylic acid isopropyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-pyridyl)pyridine-3,5-dicarboxylic acid ethyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-pyridyl)pyridine-3,5-dicarboxylic acid propyl methyl ester; and
1,4-dihydro-2,6-dimethyl-4-(4-pyridyl)pyridine-3,5-dicarboxylic acid isopropyl methyl ester.
In another preferred embodiment, the chemical compound is a symmetric derivative of 1,4-dihydropyridine-3,5-dicarboxylic acid represented by the general formula (I). Preferred chemical compounds include the symmetric C1-6-alkyl derivatives of the 1,4-dihydropyridine-3,5-dicarboxylic acid. Most preferred symmetric chemical compounds for use-according to the invention include
1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5-dicarboxylic acid dimethyl ester (Nifedipine);
1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5-dicarboxylic acid diethyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylic acid dimethyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylic acid diethyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)pyridine-3,5-dicarboxylic acid dimethyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)pyridine-3,5-dicarboxylic acid diethyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-trifluorophenyl)pyridine-3,5-dicarboxylic acid dimethyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-trifluorophenyl)pyridine-3,5-dicarboxylic acid diethyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-trifluorophenyl)pyridine-3,5-dicarboxylic acid dimethyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-trifluorophenyl)pyridine-3,5-dicarboxylic acid diethyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-trifluorophenyl)pyridine-3,5-dicarboxylic acid dimethyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-trifluorophenyl)pyridine-3,5-dicarboxylic acid diethyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-cyanophenyl)pyridine-3,5-dicarboxylic acid dimethyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-cyanophenyl)pyridine-3,5-dicarboxylic acid diethyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-cyanophenyl)pyridine-3,5-dicarboxylic acid dimethyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-cyanophenyl)pyridine-3,5-dicarboxylic acid diethyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-cyanophenyl)pyridine-3,5-dicarboxylic acid dimethyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-cyanophenyl)pyridine-3,5-dicarboxylic acid diethyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-pyridyl)pyridine-3,5-dicarboxylic acid dimethyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-pyridyl)pyridine-3,5-dicarboxylic acid diethyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-pyridyl)pyridine-3,5-dicarboxylic acid dimethyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-pyridyl)pyridine-3,5-dicarboxylic acid diethyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-pyridyl)pyridine-3,5-dicarboxylic acid dimethyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-pyridyl)pyridine-3,5-dicarboxylic acid diethyl ester;
1,4-dihydro-2,6-dimethyl-4-cyclohexylpyridine-3,5-dicarboxylic acid dimethyl ester; and
1,4-dihydro-2,6-dimethyl-4-cyclohexylpyridine-3,5-dicarboxylic acid diethyl ester.
Imidazole Derivatives
In another preferred embodiment, the chemical compound having IKCa inhibitory activity for use according to the invention is an imidazole derivative selected from the group consisting of
1-[(2-chlorophenyl)-diphenyl-methyl]-1H-imidazole (Clotrimazole);
1-[(3-chlorophenyl)-diphenyl-methyl]-1H-imidazole;
1-[(4-chlorophenyl)-diphenyl-methyl]-1H-imidazole;
1-[(2-chlorophenyl)-(4-hydroxyphenyl)-phenyl-methyl]-1H-imidazole;
1-[(3-chlorophenyl)-(4-hydroxyphenyl)-phenyl-methyl]-1H-imidazole;
1-[(4-chlorophenyl)-(4-hydroxyphenyl)-phenyl-methyl]-1H-imidazole;
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]-1H-imidazole (Miconazole);
1-Acetyl-4[4-[(2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4yl]methoxy]phenyl]piperazine (Ketoconazole);
1-[2-[(4-chlorophenyl)methoxyl]-2-(2,4-dichlorophenyl)ethyl]-1H-imidacole (Econazole);
1-[4-(4-chlorophenyl)-2-(2,6-dichlorophenylthio)butyl]imidazole mononitrate (Butoconazole);
2′,4′-dichloro-2-imidazol-1-ylacetophenone-(Z)-O-(2,4-dichlorobenzyl)oxime mononitrate (Oxiconazole);
1-[2,4-dichloro-β-(4-chlorobenzyl)thiophenethyl]imidazole nitrate (Sulconazole); and
1-[2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole (Thioconazole).
Triazole Derivatives
In a third preferred embodiment, the chemical compound having IKCa inhibitory activity for use according to the invention is a triazole derivative selected from the group consisting of
2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol (Fluconazole);
1-{4-[[2-(2,4-dichlorophenyl)r-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-c-4-yl]methoxy]-phenyl}-4-isopropylpiperazine (Terconazole);
(±)-2-sec-butyl-4-[4-(4-{4-[(2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl}-piperazin-1-yl)phenyl]-2,4-dihydro-1,2,4-triazol-3-one (Itraconazole).
Nitroimidazole Derivatives
In a fourth preferred embodiment, the chemical compound having IKCa inhibitory activity for use according to the invention is a nitroimidazole derivative selected from the group consisting of
2-methyl-5-nitroimidazole-1-ethanol (Metronidazole);
1-[2-(ethylsulphonyl)ethyl]-2-methyl-5-nitroimidazole (Tinidazole);
4-[2-(5-nitroimidazol-1-yl)ethyl]morpholine (Nimorazole);
1-chloro-3-(2-methyl-5-nitroimidazol-1-yl)propan-2-ol (Omidazole), and
N-benzyl-2-(2-nitroimidazol-1-yl)acetamide (Benznidazole).
Metabolites of Clotrimazole
In yet another preferred embodiment chemical compounds having IKCa inhibitory activity for use according to the invention are derivatives and metabolites of Clotrimazole, as described in WO 96/08242.
The derivatives and metabolites of Clotrimazole for use according to the invention may be characterised by the following general formula
Figure US06545028-20030408-C00002
wherein
X represents halogen, a trifluoromethyl group, a nitro group, or a cyano group;
R represents hydrogen, halogen, hydroxy, an alkyl group, a cycloalkyl group, an alkoxy group, or an alkyloxy group;
R1 represents hydrogen, or a phenyl group, which phenyl group may be substituted one or more times with substituents selected from the group consisting of halogen and hydroxy;
R2 represents hydrogen, hydroxyl, alkyl, alkoxy;
R3 represents a group of the formula —Y—CH2—R5, wherein Y represents oxygen (—O—) or sulphur (—S—); a group of the formula ═NO—CH2R5; a group of the formula —O-phenyl—CH═CH2; a group of the formula —CH2—CH(CH3)—S-phenyl, which phenyl may be substituted one or more times with substituents selected from the group consisting of halogen and hydroxy; or a phenyl group, which phenyl may be substituted one or more times with substituents selected from the group consisting of halogen and hydroxy; and wherein R5 represents an ethenyl group (CH2═CH—); a phenyl group, which phenyl may be substituted one or more times with substituents selected from the group consisting of halogen and hydroxy; a phenyl-S-phenyl group, a group of the formula CH2—O-phenyl, which phenyl may be substituted one or more times with substituents selected from the group consisting of halogen and hydroxy; or a group of the formula
Figure US06545028-20030408-C00003
 wherein Z represents S, O or N;
and R6 represents hydrogen, halogen or hydroxy;
or a pharmaceutically acceptable acid addition salt thereof.
Preferred derivatives and metabolites for use according to the invention include
2-chlorophenyl-4-hydroxyphenyl-phenyl-methane;
2-chlorophenyl-bis-phenyl-methane;
2-chlorophenyl-bis-phenyl-methanol;
3-(1-[2,4-dichlorophenyl]-ethoxymethyl)-2-chlorothiophene;
0-(2,4-dichlorobenzyl)-2,4-dichloroacetophenone oxime;
1-(2,4-dichloro)-1-(4-(phenylthio)benzyloxy)ethane;
1-(2,4-dichlorophenyl) 1-1(allyloxy)ethane;
1-(2,4-dichlorophenyl)-1-(4-chlorobenzylthio)ethane;
1-(2,4-dichlorophenyl)-1-(2,4-dichlorobenzyloxy)ethane;
1-(2,4-dichlorophenyl)ethyl-2,6-dichlorobenzyl ether;
1-(2-[4-chlorophenoxy]ethyloxy)-1-(2,4-dichlorophenyl)propene;
1-(2,4-dichlorophenyl)-ethyl-(4-chlorophenyl)methyl ether;
3-chlorobenzyl-2-vinylphenyl ether; and
1-(4-chlorophenyl)-3-(2,6-dichlorophenylthio)butane.
Definition of Substituents
In the context of this invention halogen represents a fluorine, a chlorine, a bromine or a iodine atom.
In the context of this invention an alkyl group designates a univalent saturated, straight or branched hydrocarbon chain. The hydrocarbon chain preferably contain of from one to eighteen carbon atoms (C1-8-alkyl), more preferred of from one to six carbon atoms (C1-6-alkyl; lower alkyl), including pentyl, isopentyl, neopentyl, tertiary pentyl, hexyl and isohexyl. In a preferred embodiment alkyl represents a C1-4-alkyl group, including butyl, isobutyl, secondary butyl, and tertiary butyl. In a most preferred embodiment alkyl represents a C1-3-alkyl group, which may in particular be methyl, ethyl, propyl or isopropyl.
In the context of this invention a cycloalkyl group designates a cyclic alkyl group, preferably containing of from three to seven carbon atoms (C3-7-cycloalkyl), including cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
In the context of this invention an alkenyl group designates a carbon chain containing one or more double bonds, including di-enes, tri-enes and poly-enes. In a preferred embodiment the alkenyl group of the invention comprises of from two to six carbon atoms (C2-6-alkenyl), including at least one double bond. In a most preferred embodiment the alkenyl group of the invention is ethenyl; 1,2- or 2,3-propenyl; or 1,2-, 2,3-, or 3,4-butenyl.
In the context of this invention an alkynyl group designates a carbon chain containing one or more triple bonds, including di-ynes, tri-ynes and poly-ynes. In a preferred embodiment the alkynyl group of the invention comprises of from two to six carbon atoms (C2-6-alkynyl), including at least one triple bond. In its most preferred embodiment the alkynyl group of the invention is ethynyl, 1,2- or 2,3-propynyl, 1,2-, 2,3- or 3,4-butynyl.
In the context of this invention an alkoxy group designates an “alkyl-O—” group, wherein alkyl is as defined above.
In the context of this invention a mono- or polycyclic aryl group designates a monocyclic or polycyclic aromatic hydrocarbon group. Examples of preferred aryl groups of the invention are phenyl, naphthyl and anthracenyl.
In the context of this invention a mono- or poly-heterocyclic group is a mono- or polycyclic aromatic group, which holds one or more heteroatoms in its ring structure. Preferred heterocyclic monocyclic groups of the invention are 5- and 6 membered heterocyclic monocyclic groups. Examples of preferred heterocyclic monocyclic groups of the invention include furanyl, imidazolyl, isoimidazolyl, 2-isoimidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, thiadiazolyl, thiazolyl, and thienyl. Examples of preferred heterocyclic polycyclic groups of the invention include benzimidazolyl, indolyl, isoquinolyl and quinolyl.
The chemical compounds for use according to the invention have been described and may be prepared by methods known in the art.
Pharmaceutically Acceptable Salts
The chemical compound of the invention may be provided in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, or pre- or prodrug forms of the chemical compound of the invention.
Examples of pharmaceutically acceptable addition salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the acetate derived from acetic acid, the aconate derived from aconitic acid, the ascorbate derived from ascorbic acid, the benzenesulfonate derived from benzensulfonic acid, the benzoate derived from benzoic acid, the cinnamate derived from cinnamic acid, the citrate derived from citric acid, the embonate derived from embonic acid, the enantate derived from enanthic acid, the formate derived from formic acid, the fumarate derived from fumaric acid, the glutamate derived from glutamic acid, the glycolate derived from glycolic acid, the hydrochloride derived from hydrochloric acid, the hydrobromide derived from hydrobromic acid, the lactate derived from lactic acid, the maleate derived from maleic acid, the malonate derived from malonic acid, the mandelate derived from mandelic acid, the methanesulfonate derived from methane sulphonic acid, the naphthalene-2-sulphonate derived from naphtalene-2-sulphonic acid, the nitrate derived from nitric acid, the perchlorate derived from perchloric acid, the phosphate derived from phosphoric acid, the phthalate derived from phthalic acid, the salicylate derived from salicylic acid, the sorbate derived from sorbic acid, the stearate derived from stearic acid, the succinate derived from succinic acids the sulphate derived from sulphuric acid, the tartrate derived from tartaric acid, the toluene-p-sulphonate derived from p-toluene sulfonic acid, and the like. Such salts may be formed by procedures well known and described in the art.
Other acids such as oxalic acid, which may not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining a chemical compound of the invention and its pharmaceutically acceptable acid addition salt.
Metal salts of a chemical compound of the invention includes alkali metal salts, such as the sodium salt, of a chemical compound of the invention containing a carboxy group.
The chemical compound of the invention may be provided in dissoluble or indissoluble forms together with a pharmaceutically acceptable solvents such as water, ethanol, and the like. Dissoluble forms may also include hydrated forms such as the monohydrate, the dihydrate, the hemihydrate, the trihydrate, the tetrahydrate, and the like. In general, the dissoluble forms are considered equivalent to indissoluble forms for the purposes of this invention.
Steric Isomers
The chemical compounds of the present invention may exist in (+) and (−) forms as well as in racemic forms. The racemates of these isomers and the individual isomers themselves are within the scope of the present invention.
Racemic forms can be resolved into the optical antipodes by known methods and techniques. One way of separating the diastereomeric salts is by use of an optically active acid, and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optical active matrix. Racemic compounds of the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallisation of d- or I- (tartrates, mandelates, or camphorsulphonate) salts for example.
The chemical compounds of the present invention may also be resolved by the formation of diastereomeric amides by reaction of the chemical compounds of the present invention with an optically active activated carboxylic acid such as that derived from (+) or (−) phenylalanine, (+) or (−) phenylglycine, (+) or (−) camphanic acid or by the formation of diastereomeric carbamates by reaction of the chemical compound of the present invention with an optically active chloroformate or the like.
Additional methods for the resolving the optical isomers are known in the art. Such methods include those described by Jaques J, Collet A, & Wilen S in “Enantiomers, Racemates, and Resolutions”, John Wiley and Sons, New York (1981).
Moreover, some of the chemical compounds of the invention being oximes, may thus exist in two forms, syn- and anti-form (Z- and E-form), depending on the arrangement of the substituents around the —C═N— double bond. A chemical compound of the present invention may thus be the syn- or the anti-form (Z- and E-form), or it may be a mixture hereof.
Method of Screening
In another aspect, the present invention provides a method for the screening of chemical compounds for inhibitory activity on an intermediate conductance Ca2+ activated potassium channel (IKCa), by which method a chemical compound having IKCa inhibitory activity is identified by its ability to inhibit hyperpolarization of the cell.
The screening method of the invention comprises the steps of
subjecting an IKCa containing cell to the action of the chemical compound to be screened, and
monitoring the membrane potential of the IKCa containing cell.
More particularly the monitoring of the membrane potential of the IKCa containing cell of step (ii) is carried out in order to monitor changes in the membrane potential caused by the action of the chemical compound.
The IKCa Containing Cell
The IKCa used in the method of the invention may be of any origin, however, preferably of human or animal origin. Also, the IKCa may be endogenous or it may be exogenous to the cell in question.
In a preferred embodiment, the IKCa of the IKCa containing cell is an ion channel that is endogenous to the cell in question, and which cell may in particular be a T- or B-lymphocyte or other cells known to express IKCa, e.g. a HeLa cell, or a cell of epithelial origin, a cell of endothelial origin, or a blood cell.
In another preferred embodiment, the IKCa of the IKCa containing cell is an ion channel that is exogenous to the cell in question, and which cell may in particular be a human embryonic kidney (HEK) cell, a HEK 293 cell, a Chinese hamster ovary (CHO) cell, a Xenopus laevis oocyte (XLO) cell, or any other cell line able to express IKCa.
The IKCa preferably is of human origin. In particular the IKCa may be isolated from salivary glands, from lung tissue, from tracheal tissue, from placenta tissue, from pancreas tissue, from lymphocytes, from colon tissue, from kidney tissue, from thymus tissue, from bone marrow, from prostate tissue, from stomach tissue, from liver tissue, from foetal liver tissue, from mammary glands, from small intestine tissue, from spleen tissue, or from lymph node tissue. Preferably the IKCa may be isolated from salivary glands, from lung tissue, from tracheal tissue, from placenta tissue, from pancreas tissue, or from lymphocytes.
In a most preferred embodiment, the IKCa is encoded by the DNA sequence presented as SEQ ID NO: 1, or a homologous sequence, e.g. a DNA sequence showing a homology to SEQ ID NO: 1 of at least 80%, more preferred at least 90%, most preferred at least 95%.
Monitoring of the Membrane Potential
According to the method of the invention the membrane potential is monitored in order to determine changes in the membrane potential. The membrane potential may be monitored using established methods.
In a preferred embodiment monitoring of the membrane potential of the IKCa containing cell is performed by patch clamp techniques, e.g. as described by Hamill, O. P., et al., Pflügers Arch. 1981 351 85-100. In a more preferred embodiment, monitoring of the membrane potential of the IKCa containing cell is performed by the automatic patch clamp method described in pending patent application DK 1151/97.
In another preferred embodiment monitoring of the membrane potential of the IKCa containing cell is performed using fluorescence methods.
In a preferred method of the invention, the IKCa containing cell is mixed with a membrane potential indicating agent, that allow for a determination of changes in the membrane potential of the cell, caused by the addition of the test compound.
The membrane potential indicating agent employed in the method of the invention may be any agent that allow monitoring of changes in the membrane potential. In a preferred embodiment, the membrane potential indicating agent is a fluorescent indicator. The fluorescent indicator must be sufficiently sensitive so as to produce a detectable change in fluorescence intensity in the presence of calcium ions.
Preferred fluorescent indicators are in particular DIBAC4(3), DiOC5(3), and DIOC2(3).
Monitoring of the membrane potential of the IKCa containing cell may then be performed by spectroscopic methods, e.g. using a FLIPR assay (Fluorescence Image Plate Reader; available from Molecular Devices), or by using the automated analysis equipment described in U.S, Pat. No. 5,670,113.
In a separate aspect the invention relates to an encompasses the chemical compounds identified by the method of the invention and their use the use of these compounds for the treatment or alleviation of diseases or conditions relating to immune dysfunction.
Biological Activity
As described above, the IKCa inhibitory compounds of the invention are useful as immune modulating agents, i.e. agents capable of regulating the immune system. More particularly, the IKCa inhibitory compounds of the present invention may be used for reducing or inhibiting undesired immunoregulatory actions.
In a preferred embodiment, the invention relates to the use of an IKCa inhibitory compound for the treatment or alleviation of a diseases, disorders or condition related to immune dysfunction.
Conditions which may benefit from this treatment include, but are not limited to diseases, disorders or conditions such as autoimmune diseases, e.g. Addison's disease, alopecia areata, Ankylosing spondylitis, hemolytic anemia (anemia haemolytica), pernicious anemia (anemia perniciosa), aphthae, aphthous stomatitis, arthritis, osteoarthritis, rheumatoid arthritis, aspermiogenese, asthma bronchiale, autoimmune asthma, autoimmune hemolysis, Bechet's disease, Boeck's disease, inflammatory bowel disease, Burkitt's lymphoma, Chron's disease, chorioiditis, colitis ulcerosa, Coeliac disease, cryoglobulinemia, dermatitis herpetiformis, dermatomyositis, insulin-dependent type I diabetes, juvenile diabetes, idiopathic diabetes insipidus, insulin-dependent diabetes mellisis, autoimmune demyelinating diseases, Dupuytren's contracture, encephalomyelitis, encephalomyelitis allergica, endophthalmia phacoanaphylactica, enteritis allergica, autoimmune enteropathy syndrome, erythema nodosum leprosum, idiopathic facial paralysis, chronic fatigue syndrome, febris rheumatica, glomerulo nephritis, Goodpasture's syndrome, Graves' disease, Hamman-Rich's disease, Hashimoto's disease, Hashimoto's thyroiditis, sudden hearing loss, sensoneural hearing loss, hepatitis chronica, Hodgkin's disease, haemoglobinuria paroxysmatica, hypogonadism, ileitis regionalis, iritis, leucopenia, leucemia, lupus erythematosus disseminatus, systemic lupus erythematosus, cutaneous lupus erythematosus, lymphogranuloma malignum, mononucleosis infectiosa, myasthenia gravis, traverse myelitis, primary idiopathic myxedema, nephrosis, ophthalmia symphatica, orchitis granulomatosa, pancreatitis, pemphigus, pemphigus vulgaris, polyarteritis nodosa, polyarthritis chronica primaria, polymyositis, polyradiculitis acuta, psoreasis, purpura, pyoderma gangrenosum, Quervain's hyreoiditis, Reiter's syndrome, sarcoidosis, ataxic sclerosis, progressive systemic sclerosis, scleritis, sclerodermia, multiple sclerosis, sclerosis disseminata, acquired spenic atrophy, infertility due to antispermatozoan antobodies, thrombocytopenia, idiopathic thrombocytopenia purpura, thymoma, acute anterior uveitis, vitiligo, AIDS, HIV, SCID and Epstein Barr virus associated diseases such as Sjorgren's syndrome, virus (AIDS or EBV) associated B cell lymphoma, parasitic diseases such as Lesihmania, and immunosuppressed disease states such as viral infections following allograft transplantations, graft vs. Host syndrome, transplant rejection, or AIDS, cancers, chronic active hepatitis diabetes, toxic chock syndrome, food poisoning, and transplant rejection.
Accordingly, in further embodiments, the invention relates to a chemical compound having IKCa inhibitory activity for use as a medicament.
More specifically the invention relates to the use of a chemical compound having IKCa inhibitory activity for use in the manufacture of a medicament for the treatment of treatment of diseases related to immune dysfunction. In a preferred embodiment the medicament is an immune system suppressing medicament (an immunosuppressivum).
Pharmaceutical Compositions
In yet another aspect the invention relates to pharmaceutical compositions for use in the treatment or alleviation of diseases, disorders or conditions related to immune dysfunction, which pharmaceutical composition comprises a therapeutically effective amount of a chemical compound having IKCa inhibitory activity, as identified by the method of the invention.
While a chemical compound of the invention for use in therapy may be administered in the form of the raw chemical compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.
In a preferred embodiment, the invention provides pharmaceutical compositions comprising the chemical compound of the invention or a pharmaceutically acceptable salt or derivative thereof together with one or more pharmaceutically acceptable carriers therefor and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
The pharmaceutical composition of the invention may be administered by any convenient route which suite the desired therapy. Preferred routes of administration include oral administration, in particular in tablet, in capsule, in dragé, in powder, or in liquid form, and parenteral administration, in particular cutaneous, subcutaneous, intramuscular, or intravenous injection. The pharmaceutical composition may be prepared by the skilled person using standard and conventional techniques appropriate to the desired formulation. When desired, compositions adapted to give sustained release of the active ingredient may be employed.
The actual dosage depend on the nature and severity of the disease being treated, and is within the discretion of the physician, and may be varied by titration of the dosage to the particular circumstances of this invention to produce the desired therapeutic effect. However, it is presently contemplated that pharmaceutical compositions containing of from about 0.1 to about 500 mg of active ingredient per individual dose, preferably of from about 1 to about 100 mg, most preferred of from about 1 to about 10 mg, are suitable for therapeutic treatments.
The active ingredient may be administered in one or several doses per day. A satisfactory result can, in certain instances, be obtained at a dosage as low as 0.1 μg/kg i.v. and 1 μg/kg p.o. The upper limit of the dosage range is presently considered to be about 10 mg/kg i.v. and 100 mg/kg p.o. Preferred ranges are from about 0.1 μg/kg to about 10 mg/kg i.v., and from about 1 μg/kg to about 100 mg/kg p.o.
In a preferred embodiment, the pharmaceutical composition of the invention comprises a chemical compound which is an imidazole derivative, in particular Clotrimazole, Miconazole, Ketonazole, Econazole, Butoconazole, Oxiconazole, Sulconazole, or Tioconazole.
In another preferred embodiment, the pharmaceutical composition of the invention comprises a chemical compound which is a nitroimidazole derivative, in particular Metronidazole, Tinidazole, Nimorazole, Ornidazole, or Benznidazole.
In yet another preferred embodiment, the pharmaceutical composition of the invention comprises a chemical compound which is a triazole derivative, in particular Fluconazole, Tercolazole, or Itraconazole.
In a further preferred embodiment, the pharmaceutical composition of the invention comprises a chemical compound which is a metabolite of Clotrimazole, in particular 2-chlorophenyl-4-hydroxy-phenyl-phenyl-methane, 2-chlorophenyl-bis-phenyl-methane, or 2-chlorophenyl-bis-phenyl-methanol.
Method of Treatment
The IKCa inhibitory compounds of the invention are useful as immune modulating agents, i.e. agents capable of regulating the immune system, and may be used in a method of for reducing or inhibiting undesired immunoregulatory actions.
Therefore, in a separate aspect, the invention relates to a method of treatment or alleviation of diseases, disorders or conditions relating to immune dysfunction in a living body, said method comprising administering to said living body an effective amount of a chemical compound having IKCa inhibitory activity.
EXAMPLES
The invention is further illustrated with reference to the following examples which are not intended to be in any way limiting to the scope of the invention as claimed.
Example 1
Isolation of a cDNA Encoding Human Placenta Ca2+-activated, Intermediate Conductance Potassium Channel Protein
The full length coding sequence of a cDNA encoding human placenta Ca2+-activated, intermediate conductance potassium channel protein (SEQ ID NO: 2) is radio labelled by random priming and used as a hybridisation probe to screen a human placenta cDNA library under hybridisation. conditions of 1 M NaCl, 1% SDS and 50% formamide at 42° C. Hybridisation wash conditions are 55° C., 0.2×SSC and 0.1% SDS. Positively hybridising clones are purified and the nucleotide and predicted amino acid sequence are determined.
Example 2
Assay for DNA Encoding Ca2+-activated, Intermediate Conductance Potassium Channel Protein
The presence of DNA encoding human placenta Ca2+-activated, intermediate conductance potassium channel protein was determined by transfecting mammalian cells with a cDNA preparation and using the membrane patch clamp technique [Hamill, O. P., et al., Pflügers Arch. 1981 351 85-100] or using the Fluorescence Image Plate Reader (FLIPR) assay.
A cDNA encoding the human placenta Ca2+-activated, intermediate conductance potassium channel protein was identified by a BLAST search of the expressed sequence tag (EST) database using the query sequence (51 Amino acids):
LGHRRALFEKRKRLSDYALIFGMFGIVVMVIETELSWGLYSKDSMFSLALC  (SEQ ID NO: 3),
and allowing for mismatches.
A BLAST search retrieved the GenBank Entry No. N56819, a cDNA encoding the entire Ca2+-activated, intermediate conductance potassium channel protein.
HEK293 or CHO tissue culture cells were grown in DMEM (Dulbecco's Modified Eagle Medium) supplemented with 10% FCS (foetal calf serum) at 37° C. in 5% CO2. One day prior to transfection, 106 cells were plated in a cell culture T25 flask. The following day, cells were transfected using lipofection (20 μL Lipofectamin™, Life Technologies, with 2.5 μg of the plasmid pNS2Z_hIK2 in a total volume of 540 μL).
Two different plasmids were used for transfection. Cells prepared for the electrophysiological screening were transfected with pNS2Z_hIK2, which besides coding for the human placenta Ca2+-activated intermediate conductance potassium channel protein also codes for the green fluorescent protein EGFP. Cells prepared for the FLIPR assay were transfected with pNS1Z_hIK2, which is an analogue to pNS2Z_hIK2 but without the cDNA encoding EGFP. The lipofection mixture was overlaid on the cells and incubated at 37° C. for 5 hours. The cells were then rinsed with regular media and plated either to 30 mm culture dishes (eletrophysiological assay) or to 96-well microtiter plates (FLIPR assay).
18-48 hours after transfection cells were assayed for the presence of Ca2+-activated, intermediate conductance potassium channel protein.
Transfected HEK293 cells were assayed for the presence of Ca2+-activated, intermediate conductance potassium channel protein by a fluometric technique based on the membrane potential sensitive dye DIBAC4(3). After transfection, cells were washed twice with a 5 μM DIBAC4(3)/FLIPR buffer solution (100 μl in each well). The FLIPR buffer solution contained in mM: 145 NaCl, 1 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES, 10 glucose and with pH adjusted to 7.4. After the cell wash 180 μl DIBAC4(3)/FLIPR buffer solution was added to each well and the microtiter plate was equilibrated at 35° C. for 20-30 min. A drugplate containing lonomycin and Thapsigargin was made 10× concentrated and was also equilibrated at 35° C. before starting the experiment.
The FLIPR was programmed to do a sample reading every 20 sec. for a total period of 10 min. The assay was started with a pre-run for 1 min, followed by a simultaneous addition of 20 μl “drug” to all 96 wells. Addition of lonomycin and Thapsigargin both result in an increase in the intracellular Ca2+concentration, which in turn activated the intermediate conductance potassium channels. This activation was observed as a decrease in the fluorescent signal which correlates to a membrane hyperpolarization.
Example 3
Assays for DNA Encoding Ca2+-activated, Intermediate Conductance Potassium Channel Protein.
HEK293 or CHO tissue culture cells were grown in DMEM (Dulbecco's Modified Eagle Medium) supplemented with 10% FCS (foetal calf serum) at 37° C. in 5% CO2. One day prior to transfection, 106 cells were plated in a cell culture T25 flask. The following day, cells were transfected using lipofection (20 μL Lipofectamin™, Life Technologies, with 2.5 μg of the plasmid pNS2Z_hIK2 in a total volume of 540 μL). The lipofection mixture was overlaid on the cells and incubated at 37° C. for 5 hours.
The cells were then rinsed with regular media and plated to a 30 mm culture dish. 18-48 hours after, transfected cells were assayed for the presence of Ca2+-activated, intermediate conductance potassium channel protein by electrophysiological measurements.
The presence of DNA encoding human placenta Ca2+-activated, intermediate conductance potassium channel protein was determined by transfecting mammalian cells with a cDNA preparation and by using the patch clamp technique (see Hamill O P et al., Pflüagers Arch. 1981 351 85-100).
Whole cell currents were recorded using a pipette solution of 144 mM KCl, 1 mM EGTA, 9 mM NTA, 1.085 mM CaCl2, 5.54 mM MgCl2, and 10 mM HEPES (pH 7.2) and a bath solution of 144 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 0.01% (w/v) BSA and 10 mM HEPES (pH=7.4). Current traces were recorded from cells containing human Ca2+-activated, intermediate conductance potassium channels after application of voltage ramps (−100 mV to +100 mV, 200 ms duration).
Clotrimazole sensitivity of the expressed channels was determined by addition of 1 μM Clotrimazole to the bath solution. Application of Clotrimazole resulted in an inhibition of the Ca2+-activated potassium current which was reversed by washout of Clotrimazole from the bath solution.
An IC50 value of 153 nM for Clotrimazole was calculated from the kinetics of the block.
Example 4
Inhibition of T Cell Proliferation
The chemical compounds used according to the invention prevent immunological proliferation by selective inhibition of the Ca2+-activated K-channels in T- and B-lymphocytes. This effect may be verified using various proliferation assays. In this experiment the proliferative assay described by Ødum et al. [Ødum N, Kanner S B, Ledbetter J A, & Svejgaard A; J. Immunol. 1993 150 (12) 5289-5298] was used.
The chemical compounds representative of the invention tested in this experiment are Nitrendipine, a derivative of the 1,4-dihydropyridine-3,5-dicarboxylic acid, and the imidazole derivative Clotrimazole.
Assays were performed in culture medium (RPMI 1640; available from Gibco, Grand island, N.Y.) supplemented with 10% pooled human serum, 2 mM L-glutamine, 100 μg/ml penicillin, and 100 μg/ml streptomycin (available from Novo Nordisk, Copenhagen, Denmark) in 96-well round bottom tissue culture plates (available from Nunc, Roskilde, Denmark) with a final volume of 200 μl.
T cells were preincubated for three hours with the test compounds before addition of antigen (crude Candida albicans extract, 10 μg/ml). T cells were cultured at 5×104 cells/well for 144 hours. Twelve hours before harvest, [3H]thymidine (1× Ci/well) was added. The cells were harvested onto glass fibre filters, and the [3H]thymidine incorporation was measured in a scintillation counter. The results were expressed as mean counts per minute (cpm) from triplicate cultures.
TABLE 1
Inhibition of T Cell Proliferation
T Cell Proliferation
(cpm × 10−3)
Medium Antigen
Solvent 1 μM 5 μM 10 μM
Clotrimazole 0.2 5.8 4.2 1.8
Nitrendipine 0.2 5.6 3.8 4.0
These results show that the number of T cells decreases in the presence of increasing concentrations of the chemical compound of the invention, and support the fact that the chemical compounds of the invention inhibit the antigen induced T cell proliferation and thus are useful for the reduction or inhibition of undesired immunoregulatory actions.
3 1 1284 DNA Homo sapiens CDS (1)..(1284) 1 atg ggc ggg gat ctg gtg ctt ggc ctg ggg gcc ttg aga cgc cga aag 48 Met Gly Gly Asp Leu Val Leu Gly Leu Gly Ala Leu Arg Arg Arg Lys 1 5 10 15 cgc ttg ctg gag cag gag aag tct ctg gcc ggc tgg gca ctg gtg ctg 96 Arg Leu Leu Glu Gln Glu Lys Ser Leu Ala Gly Trp Ala Leu Val Leu 20 25 30 gca gga act ggc att gga ctc atg gtg ctg cat gca gag atg ctg tgg 144 Ala Gly Thr Gly Ile Gly Leu Met Val Leu His Ala Glu Met Leu Trp 35 40 45 ttc ggg ggg tgc tcg tgg gcg ctc tac ctg ttc ctg gtt aaa tgc acg 192 Phe Gly Gly Cys Ser Trp Ala Leu Tyr Leu Phe Leu Val Lys Cys Thr 50 55 60 atc agc att tcc acc ttc tta ctc ctc tgc ctc atc gtg gcc ttt cat 240 Ile Ser Ile Ser Thr Phe Leu Leu Leu Cys Leu Ile Val Ala Phe His 65 70 75 80 gcc aaa gag gtc cag ctg ttc atg acc gac aac ggg ctg cgg gac tgg 288 Ala Lys Glu Val Gln Leu Phe Met Thr Asp Asn Gly Leu Arg Asp Trp 85 90 95 cgc gtg gcg ctg acc ggg cgg cag gcg gcg cag atc gtg ctg gag ctg 336 Arg Val Ala Leu Thr Gly Arg Gln Ala Ala Gln Ile Val Leu Glu Leu 100 105 110 gtg gtg tgt ggg ctg cac ccg gcg ccc gtg cgg ggc ccg ccg tgc gtg 384 Val Val Cys Gly Leu His Pro Ala Pro Val Arg Gly Pro Pro Cys Val 115 120 125 cag gat tta ggg gcg ccg ctg acc tcc ccg cag ccc tgg ccg gga ttc 432 Gln Asp Leu Gly Ala Pro Leu Thr Ser Pro Gln Pro Trp Pro Gly Phe 130 135 140 ctg ggc caa ggg gaa gcg ctg ctg tcc ctg gcc atg ctg ctg cgt ctc 480 Leu Gly Gln Gly Glu Ala Leu Leu Ser Leu Ala Met Leu Leu Arg Leu 145 150 155 160 tac ctg gtg ccc cgc gcc gtg ctc ctg cgc agc ggc gtc ctg ctc aac 528 Tyr Leu Val Pro Arg Ala Val Leu Leu Arg Ser Gly Val Leu Leu Asn 165 170 175 gct tcc tac cgc agc atc ggc gct ctc aat caa gtc cgc ttc cgc cac 576 Ala Ser Tyr Arg Ser Ile Gly Ala Leu Asn Gln Val Arg Phe Arg His 180 185 190 tgg ttc gtg gcc aag ctt tac atg aac acg cac cct ggc cgc ctg ctg 624 Trp Phe Val Ala Lys Leu Tyr Met Asn Thr His Pro Gly Arg Leu Leu 195 200 205 ctc ggc ctc acg ctt ggc ctc tgg ctg acc acc gcc tgg gtg ctg tcc 672 Leu Gly Leu Thr Leu Gly Leu Trp Leu Thr Thr Ala Trp Val Leu Ser 210 215 220 gtg gcc gag agg cag gct gtt aat gcc act ggg cac ctt tca gac aca 720 Val Ala Glu Arg Gln Ala Val Asn Ala Thr Gly His Leu Ser Asp Thr 225 230 235 240 ctt tgg ctg att ccc atc aca ttc ctg acc atc ggc tat ggt gac gtg 768 Leu Trp Leu Ile Pro Ile Thr Phe Leu Thr Ile Gly Tyr Gly Asp Val 245 250 255 gtg ccg ggc acc atg tgg ggc aag atc gtc tgc ctg tgc act gga gtc 816 Val Pro Gly Thr Met Trp Gly Lys Ile Val Cys Leu Cys Thr Gly Val 260 265 270 atg ggt gtc tgc tgc aca gcc ctg ctg gtg gcc gtg gtg gcc cgg aag 864 Met Gly Val Cys Cys Thr Ala Leu Leu Val Ala Val Val Ala Arg Lys 275 280 285 ctg gag ttt aac aag gca gag aag cac gtg cac aac ttc atg atg gat 912 Leu Glu Phe Asn Lys Ala Glu Lys His Val His Asn Phe Met Met Asp 290 295 300 atc cag tat acc aaa gag atg aag gag tcc gct gcc cga gtg cta caa 960 Ile Gln Tyr Thr Lys Glu Met Lys Glu Ser Ala Ala Arg Val Leu Gln 305 310 315 320 gaa gcc tgg atg ttc tac aaa cat act cgc agg aag gag tct cat gct 1008 Glu Ala Trp Met Phe Tyr Lys His Thr Arg Arg Lys Glu Ser His Ala 325 330 335 gcc cgc agg cat cag cgc aag ctg ctg gcc gcc atc aac gcg ttc cgc 1056 Ala Arg Arg His Gln Arg Lys Leu Leu Ala Ala Ile Asn Ala Phe Arg 340 345 350 cag gtg cgg ctg aaa cac cgg aag ctc cgg gaa caa gtg aac tcc atg 1104 Gln Val Arg Leu Lys His Arg Lys Leu Arg Glu Gln Val Asn Ser Met 355 360 365 gtg gac atc tcc aag atg cac atg atc ctg tat gac ctg cag cag aat 1152 Val Asp Ile Ser Lys Met His Met Ile Leu Tyr Asp Leu Gln Gln Asn 370 375 380 ctg agc agc tca cac cgg gcc ctg gag aaa cag att gac acg ctg gcg 1200 Leu Ser Ser Ser His Arg Ala Leu Glu Lys Gln Ile Asp Thr Leu Ala 385 390 395 400 ggg aag ctg gat gcc ctg act gag ctg ctt agc act gcc ctg ggg ccg 1248 Gly Lys Leu Asp Ala Leu Thr Glu Leu Leu Ser Thr Ala Leu Gly Pro 405 410 415 agg cag ctt cca gaa ccc agc cag cag tcc aag tag 1284 Arg Gln Leu Pro Glu Pro Ser Gln Gln Ser Lys 420 425 2 427 PRT Homo sapiens 2 Met Gly Gly Asp Leu Val Leu Gly Leu Gly Ala Leu Arg Arg Arg Lys 1 5 10 15 Arg Leu Leu Glu Gln Glu Lys Ser Leu Ala Gly Trp Ala Leu Val Leu 20 25 30 Ala Gly Thr Gly Ile Gly Leu Met Val Leu His Ala Glu Met Leu Trp 35 40 45 Phe Gly Gly Cys Ser Trp Ala Leu Tyr Leu Phe Leu Val Lys Cys Thr 50 55 60 Ile Ser Ile Ser Thr Phe Leu Leu Leu Cys Leu Ile Val Ala Phe His 65 70 75 80 Ala Lys Glu Val Gln Leu Phe Met Thr Asp Asn Gly Leu Arg Asp Trp 85 90 95 Arg Val Ala Leu Thr Gly Arg Gln Ala Ala Gln Ile Val Leu Glu Leu 100 105 110 Val Val Cys Gly Leu His Pro Ala Pro Val Arg Gly Pro Pro Cys Val 115 120 125 Gln Asp Leu Gly Ala Pro Leu Thr Ser Pro Gln Pro Trp Pro Gly Phe 130 135 140 Leu Gly Gln Gly Glu Ala Leu Leu Ser Leu Ala Met Leu Leu Arg Leu 145 150 155 160 Tyr Leu Val Pro Arg Ala Val Leu Leu Arg Ser Gly Val Leu Leu Asn 165 170 175 Ala Ser Tyr Arg Ser Ile Gly Ala Leu Asn Gln Val Arg Phe Arg His 180 185 190 Trp Phe Val Ala Lys Leu Tyr Met Asn Thr His Pro Gly Arg Leu Leu 195 200 205 Leu Gly Leu Thr Leu Gly Leu Trp Leu Thr Thr Ala Trp Val Leu Ser 210 215 220 Val Ala Glu Arg Gln Ala Val Asn Ala Thr Gly His Leu Ser Asp Thr 225 230 235 240 Leu Trp Leu Ile Pro Ile Thr Phe Leu Thr Ile Gly Tyr Gly Asp Val 245 250 255 Val Pro Gly Thr Met Trp Gly Lys Ile Val Cys Leu Cys Thr Gly Val 260 265 270 Met Gly Val Cys Cys Thr Ala Leu Leu Val Ala Val Val Ala Arg Lys 275 280 285 Leu Glu Phe Asn Lys Ala Glu Lys His Val His Asn Phe Met Met Asp 290 295 300 Ile Gln Tyr Thr Lys Glu Met Lys Glu Ser Ala Ala Arg Val Leu Gln 305 310 315 320 Glu Ala Trp Met Phe Tyr Lys His Thr Arg Arg Lys Glu Ser His Ala 325 330 335 Ala Arg Arg His Gln Arg Lys Leu Leu Ala Ala Ile Asn Ala Phe Arg 340 345 350 Gln Val Arg Leu Lys His Arg Lys Leu Arg Glu Gln Val Asn Ser Met 355 360 365 Val Asp Ile Ser Lys Met His Met Ile Leu Tyr Asp Leu Gln Gln Asn 370 375 380 Leu Ser Ser Ser His Arg Ala Leu Glu Lys Gln Ile Asp Thr Leu Ala 385 390 395 400 Gly Lys Leu Asp Ala Leu Thr Glu Leu Leu Ser Thr Ala Leu Gly Pro 405 410 415 Arg Gln Leu Pro Glu Pro Ser Gln Gln Ser Lys 420 425 3 51 PRT Artificial Sequence Query sequence used to identify a cDNA encoding the human placenta Ca2+- activated, intermediate conductance potassium channel protein via a BLAST search of the EST database 3 Leu Gly His Arg Arg Ala Leu Phe Glu Lys Arg Lys Arg Leu Ser Asp 1 5 10 15 Tyr Ala Leu Ile Phe Gly Met Phe Gly Ile Val Val Met Val Ile Glu 20 25 30 Thr Glu Leu Ser Trp Gly Leu Tyr Ser Lys Asp Ser Met Phe Ser Leu 35 40 45 Ala Leu Cys 50

Claims (6)

What is claimed is:
1. A method for treatment or alleviation of a disease, condition or disorder selected from the group consisting of inflammatory bowel disease, Chron's disease, colitis ulcerosa, Coeliac disease, dermatitis herpetiformis, dermatomyositis, enteritis allergia, erytherma nodosum leprosum, ileitis regionalis, psoriasis, purpura, scleritis or scleroderma, said method comprising administering to a living body in need thereof an effective amount at least one compound selected from the group consisting of
an imidazole derivative selected from the group consisting of
1-[(2-chlorophenyl)-diphenyl-methyl]-1H-imidazole (Clotrimazole);
1-[(3-chlorophenyl)-diphenyl-methyl]-1H-imidazole;
1-[(4-chlorophenyl)-diphenyl-methyl]-1H-imidazole;
1-[(2-chlorophenyl)-(4-hydroxyphenyl)-phenyl-methyl]-1H-imidazole;
1-[(3-chlorophenyl)-(4-hydroxyphenyl)-phenyl-methyl]-1H-imidazole;
1-[(4-chlorophenyl)-(4-hydroxyphenyl)-phenyl-methyl]-1H-imidazole;
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]-1H-imidazole (Miconazole);
1-Acetyl-4[4-[(2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4yl]methoxy]phenyl]piperazine (Ketoconazole);
1-[2-[(4-chlorophenyl)methoxyl]-2-(2,4-dichlorophenyl)ethyl]-1H-imidacole (Econazole);
1-[4-(4-chlorophenyl)-2-(2,6-dichlorophenylthio)butyl]imidazole mononitrate (Butoconazole);
2′,4′-dichloro-2-imidazol-1-ylacetophenone-(Z)—O—(2,4-dichlorobenzyl)oxime mononitrate (Oxiconazole);
1-[2,4-dichloro-β-(4-chlorobenzyl)thiophenethyl]imidazole nitrate (Sulconazole); and
1-[2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole (Thioconazole);
a triazole derivative selected from the group consisting of
2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol (Fluconazole);
1-{4-[[2-(2,4-dichlorophenyl)r-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-c-4-yl]methoxy]-phenyl}-4-isopropylpiperazine (Terconazole); and
(±)-2-sec-butyl-4-[4-(4-{4-[(2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl}-piperazin-1-yl)phenyl]-2,4-dihydro-1,2,4-triazol-3-one (Itraconazole); and
a nitroimidazole derivative selected from the group consisting of
2-methyl-5-nitroimidazole-1-ethanol (Metronidazole);
1-[2-(ethylsulphonyl)ethyl]-2-methyl-5-nitroimidazole (Tinidazole);
4-[2-(5-nitroimidazol-1-yl)ethyl]morpholine (Nimorazole);
1-chloro-3-(2-methyl-5-nitroimidazol-1-yl)propan-2-ol (Ornidazole); and
N-benzyl-2-(2-nitroimidazol-1-yl)acetamide (Benznidazole).
2. The method of claim 1, wherein the disease, disorder or condition is dermatitis herpetiformis, dermatomyosis, enteritis allergia, psoriasis, scleritis or scleroderma.
3. The method of claim 2, said method comprising administering to said living body an effective amount of 1-[(2-chlorophenyl)-diphenyl-methyl]-1H-imidazol (Clotrimazole).
4. The method of claim 3, wherein the disease, disorder or condition is psoriasis.
5. A method for treatment or alleviation of a disease, condition or disorder selected from the group consisting of inflammatory bowel disease, Chron's disease, colitis ulcerosa, Coeliac disease, dermatitis herpetiformis, dermatomyositis, enteritis allergia, erytherma nodosum leprosum, ileitis regionalis, psoriasis, purpura, scleritis or scleroderma, said method comprising administering to a living body in need thereof an effective amount of 1,4-dihydropyridine-3,5-dicarboxylic acid derivative selected from the group consisting of
1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5-dicarboxylic acid ethyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5-dicarboxylic acid propyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5-dicarboxylic acid isopropyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylic acid ethyl methyl ester (Nitrendipine);
1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylic acid propyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylic acid isopropyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)pyridine-3,5-dicarboxylic acid ethyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)pyridine-3,5-dicarboxylic acid propyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)pyridine-3,5-dicarboxylic acid isopropyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-trifluorophenyl)pyridine-3,5-dicarboxylic acid ethyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-trifluorophenyl)pyridine-3,5-dicarboxylic acid propyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-trifluorophenyl)pyridine-3,5-dicarboxylic acid isopropyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-trifluorophenyl)pyridine-3,5-dicarboxylic acid ethyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-trifluorophenyl)pyridine-3,5-dicarboxylic acid propyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-trifluorophenyl)pyridine-3,5-dicarboxylic acid isopropyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-trifluorophenyl)pyridine-3,5-dicarboxylic acid ethyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-trifluorophenyl)pyridine-3,5-dicarboxylic acid propyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-trifluorophenyl)pyridine-3,5-dicarboxylic acid isopropyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-cyanophenyl)pyridine-3,5-dicarboxylic acid ethyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-cyanophenyl)pyridine-3,5-dicarboxylic acid propyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-cyanophenyl)pyridine-3,5-dicarboxylic acid isopropyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-cyanophenyl)pyridine-3,5-dicarboxylic acid ethyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-cyanophenyl)pyridine-3,5-dicarboxylic acid propyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-cyanophenyl)pyridine-3,5-dicarboxylic acid isopropyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-cyanophenyl)pyridine-3,5-dicarboxylic acid ethyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-cyanophenyl)pyridine-3,5-dicarboxylic acid propyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-cyanophenyl)pyridine-3,5-dicarboxylic acid isopropyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-pyridyl)pyridine-3,5-dicarboxylic acid ethyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-pyridyl)pyridine-3,5-dicarboxylic acid propyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(2-pyridyl)pyridine-3,5-dicarboxylic acid isopropyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-pyridyl)pyridine-3,5-dicarboxylic acid ethyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-pyridyl)pyridine-3,5-dicarboxylic acid propyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(3-pyridyl)pyridine-3,5-dicarboxylic acid isopropyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-pyridyl)pyridine-3,5-dicarboxylic acid ethyl methyl ester;
1,4-dihydro-2,6-dimethyl-4-(4-pyridyl)pyridine-3,5-dicarboxylic acid propyl methyl ester; and
1,4-dihydro-2,6-dimethyl-4-(4-pyridyl)pyridine-3,5-dicarboxylic acid isopropyl methyl ester.
6. The method of claim 5, said method comprising administering to said living body an effective amount of 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylic acid ethyl methyl ester (Nitrendipine).
US09/550,645 1997-11-14 2000-04-14 Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction Expired - Fee Related US6545028B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK129897 1997-11-14
DK1298/97 1997-11-14
DK38698 1998-03-19
DK0386/98 1998-03-19
PCT/DK1998/000490 WO1999025347A2 (en) 1997-11-14 1998-11-13 Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1998/000490 Continuation WO1999025347A2 (en) 1997-11-14 1998-11-13 Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction

Publications (2)

Publication Number Publication Date
US20020119989A1 US20020119989A1 (en) 2002-08-29
US6545028B2 true US6545028B2 (en) 2003-04-08

Family

ID=26063900

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/550,645 Expired - Fee Related US6545028B2 (en) 1997-11-14 2000-04-14 Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction

Country Status (4)

Country Link
US (1) US6545028B2 (en)
EP (1) EP1052990A2 (en)
AU (1) AU1224599A (en)
WO (1) WO1999025347A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077660A1 (en) * 1994-08-09 2004-04-22 Per Marin Method for treating insulin resistance, abdominal obesity, hypertension, hyperinsulinemia, and elevated blood lipids with a cortisol inhibitor
WO2005027851A2 (en) 2003-09-18 2005-03-31 Children's Medical Center Corporation Treatment of severe distal colitis
US20060148770A1 (en) * 2002-06-10 2006-07-06 Jason Fong Combinations for the treatment of rheumatoid arithritis
US7235577B1 (en) * 2000-01-06 2007-06-26 The Regents Of The University Of California Non-peptide inhibition of T-lymphocyte activation and therapies related thereto
US20130281504A1 (en) * 2010-06-28 2013-10-24 The Regents Of The University Of California Reduction of Microglia-Mediated Neurotoxicity by KCa3.1 Inhibition
WO2014159343A1 (en) * 2013-03-14 2014-10-02 Celtaxsys, Inc. Method of stimulating immune cell migration
US10343997B1 (en) 2018-12-04 2019-07-09 King Saud University Ursolic acid derivatives

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4376970B2 (en) 1996-03-20 2009-12-02 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Triarylmethane compounds for sickle cell disease
US5889038A (en) 1996-03-20 1999-03-30 Children's Hospital Methods and products for treating diarrhea and scours: use of clotrimazole and related aromatic compounds
JP4052525B2 (en) 1996-09-11 2008-02-27 オレゴン ヘルス サイエンシーズ ユニバーシティー Low and intermediate conductance calcium activated potassium channels and uses thereof
WO2000069439A1 (en) * 1999-05-12 2000-11-23 Neurosearch A/S Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction
EP1187610A2 (en) 1999-05-12 2002-03-20 Neurosearch A/S Use of ion channel modulating agents
CA2433041A1 (en) * 2000-12-28 2002-07-11 Switch Biotech Aktiengesellschaft Use of intermediate-conductance potassium channels and modulators for diagnosing and treating diseases involving disturbed keratinocyte activiyty
US20100056637A1 (en) * 2005-12-20 2010-03-04 Icagen, Inc. Treatment methods using triaryl methane compounds
US20070185209A1 (en) * 2005-12-20 2007-08-09 Icagen, Inc. Treatment methods using triaryl methane compounds
EP1800673A3 (en) * 2005-12-23 2007-08-15 Canadian Blood Services Nitrophenyls and related compounds and thimerosal for the inhibition of immune related cell or tissue destruction
WO2009078934A1 (en) * 2007-12-14 2009-06-25 Merck & Co., Inc. Mineralocorticoid receptor modulators
US8932154B2 (en) 2007-12-28 2015-01-13 Taylor Made Golf Company, Inc. Golf ball with softer feel and high iron spin
CN101575314B (en) * 2009-06-25 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 Dihydropyridine compounds and application thereof on preparing drugs for curing and/or preventing virus diseases
EP4251611A4 (en) * 2020-11-30 2025-01-15 Nanyang Technological University POTENT AND SELECTIVE INHIBITORS OF CALCIUM-ACTIVATED POTASSIUM CHANNELS Kca3.1 FOR USE AS THERAPEUTIC PLATFORMS

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660577A (en) * 1967-09-15 1972-05-02 Bayer Ag N-trityl-imidazoles as antifungal agents
US3799934A (en) 1971-04-10 1974-03-26 Bayer Ag Unsymmetrical esters of 1,4-dihydropyridine 3,5-dicarboxylic acid
US4073922A (en) * 1976-01-01 1978-02-14 John R. A. Simoons Treatment of rheumatoid arthritis and related diseases
US4267169A (en) * 1978-07-22 1981-05-12 Toko Yakuhin Kogyo Kabushiki Kaisha Novel preparation of clotrimazole
US4435409A (en) 1981-12-10 1984-03-06 Usv Pharmaceutical Corporation Method of stimulating production of IgM antibodies
US4952594A (en) * 1973-06-18 1990-08-28 Mercer James B Reagents and method for therapeutic treatment of multiple sclerosis
EP0531598A1 (en) 1988-01-21 1993-03-17 Alter, S.A. 1,4-Dihydropyridines with paf-antagonistic activity
US5273992A (en) 1992-11-02 1993-12-28 Beth Israel Hospital Assoc. Inc. Method for reducing sickle erythrocyte dehydration and delaying the occurrence of erythrocyte sickling in-situ
WO1995021943A1 (en) 1994-02-08 1995-08-17 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Dna encoding atp-sensitive potassium channel proteins and uses thereof
US5478848A (en) * 1994-01-26 1995-12-26 Bayer Corporation Inhibition of arthritis by L-type calcium channel antagonists nimodipine, nisoldipine and nifedipine
WO1996008242A2 (en) 1994-09-16 1996-03-21 Children's Medical Center Corporation Clotrimazole metabolites in the treatment of sickle cell disease
JPH08225450A (en) 1995-02-21 1996-09-03 Green Cross Corp:The Lipid oxidation inhibitor
US5670113A (en) 1991-12-20 1997-09-23 Sibia Neurosciences, Inc. Automated analysis equipment and assay method for detecting cell surface protein and/or cytoplasmic receptor function using same
WO1997034589A1 (en) 1996-03-20 1997-09-25 President And Fellows Of Harvard College Triaryl methane compounds for sickle cell disease
WO1997035991A1 (en) 1996-03-28 1997-10-02 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660577A (en) * 1967-09-15 1972-05-02 Bayer Ag N-trityl-imidazoles as antifungal agents
US3799934A (en) 1971-04-10 1974-03-26 Bayer Ag Unsymmetrical esters of 1,4-dihydropyridine 3,5-dicarboxylic acid
US4952594A (en) * 1973-06-18 1990-08-28 Mercer James B Reagents and method for therapeutic treatment of multiple sclerosis
US4073922A (en) * 1976-01-01 1978-02-14 John R. A. Simoons Treatment of rheumatoid arthritis and related diseases
US4267169A (en) * 1978-07-22 1981-05-12 Toko Yakuhin Kogyo Kabushiki Kaisha Novel preparation of clotrimazole
US4435409A (en) 1981-12-10 1984-03-06 Usv Pharmaceutical Corporation Method of stimulating production of IgM antibodies
EP0531598A1 (en) 1988-01-21 1993-03-17 Alter, S.A. 1,4-Dihydropyridines with paf-antagonistic activity
US5670113A (en) 1991-12-20 1997-09-23 Sibia Neurosciences, Inc. Automated analysis equipment and assay method for detecting cell surface protein and/or cytoplasmic receptor function using same
US5273992A (en) 1992-11-02 1993-12-28 Beth Israel Hospital Assoc. Inc. Method for reducing sickle erythrocyte dehydration and delaying the occurrence of erythrocyte sickling in-situ
US5478848A (en) * 1994-01-26 1995-12-26 Bayer Corporation Inhibition of arthritis by L-type calcium channel antagonists nimodipine, nisoldipine and nifedipine
WO1995021943A1 (en) 1994-02-08 1995-08-17 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Dna encoding atp-sensitive potassium channel proteins and uses thereof
WO1996008242A2 (en) 1994-09-16 1996-03-21 Children's Medical Center Corporation Clotrimazole metabolites in the treatment of sickle cell disease
JPH08225450A (en) 1995-02-21 1996-09-03 Green Cross Corp:The Lipid oxidation inhibitor
WO1997034589A1 (en) 1996-03-20 1997-09-25 President And Fellows Of Harvard College Triaryl methane compounds for sickle cell disease
WO1997035991A1 (en) 1996-03-28 1997-10-02 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
Akula et al. Drug Design and Delivery, vol. 7, pp. 11-17 (1990).
Akula et al. Pharmaceutical Research, vol. 7, No. 9, pp. 919-922 (1990).
Akula et al., Drug Design and Delivery, vol. 5, pp. 117-123 (1989).
Brugnara et al., The American Society for Clinical Investigation, Inc. vol. 97, No. 5, pp. 1227-1234 (1996).
Brugnara et al., The Journal of Pharmacology and Experimental Therapeutics, vol. 273, No. 1, pp. 266-272 (1995).
Case et al., Cell Calcium, pp. 1-17 (1997).
Dagnino et al. American Chemical Society, pp. 2524-2529 (1986).
Ellory et al., Br. J. Pharmacol, pp. 903-905 (1994).
Hamill, O.P., Pflügers Arch., vol. 391 (1981) pp. 85-100.
Odum et al., The Journal of Immunology, vol. 150, No. 12, pp. 5289-5298 (1993).
Rader et al., T. Cell Activation is Regulated by Voltage-Dependent and Calcium-Activated Potassium Channels, pp. 1425-1430 (1996).
Ramesh et al. Drug Design and Delivery, vol. 2, pp. 79-89 (1987).
Randriamampita et al., Cell Calcium, pp. 313-323 (1991).
Schwab, Ion Channel Modulators, vol. 3, No. 4, pp. 126-129 (1998).
Tacke et al., Immunobiology, pp. 138-139 (1994).
Urbahns, Bayer AG, pp. 1 (1998).
Wynn et al., Drug Design and Delivery, vol. 3, pp. 245-256 (1988).

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077660A1 (en) * 1994-08-09 2004-04-22 Per Marin Method for treating insulin resistance, abdominal obesity, hypertension, hyperinsulinemia, and elevated blood lipids with a cortisol inhibitor
US7960410B2 (en) 1994-08-09 2011-06-14 Cortendo Ab Method for treating insulin resistance, abdominal obesity, hypertension, hyperinsulinemia, and elevated blood lipids with a cortisol inhibitor
US20060014758A1 (en) * 1994-08-09 2006-01-19 Per Marin Method for treating insulin resistance, abdominal obesity, hypertension, hyperinsulinemia, and elevated blood lipids with a cortisol inhibitor
US7872008B2 (en) 1994-08-09 2011-01-18 Cortendo Ab Method for treating insulin resistance, abdominal obesity, hypertension, hyperinsulinemia, and elevated blood lipids with a cortisol inhibitor
US7235577B1 (en) * 2000-01-06 2007-06-26 The Regents Of The University Of California Non-peptide inhibition of T-lymphocyte activation and therapies related thereto
US20070293554A1 (en) * 2000-01-06 2007-12-20 The Regents Of The University Of California Non-peptide inhibition of T-lymphocyte activation and therapies related thereto
US20060148770A1 (en) * 2002-06-10 2006-07-06 Jason Fong Combinations for the treatment of rheumatoid arithritis
US20070259841A1 (en) * 2002-06-10 2007-11-08 Combinatorx, Incorporated Combinations for the treatment of rheumatoid arthritis
US20090118343A1 (en) * 2003-09-18 2009-05-07 Children's Medical Center Corporation Treatment of severe distal colitis
AU2004274016B2 (en) * 2003-09-18 2010-05-13 Children's Medical Center Corporation Treatment of severe distal colitis
WO2005027851A3 (en) * 2003-09-18 2006-03-30 Childrens Medical Center Treatment of severe distal colitis
WO2005027851A2 (en) 2003-09-18 2005-03-31 Children's Medical Center Corporation Treatment of severe distal colitis
US9072728B2 (en) 2003-09-18 2015-07-07 Children's Medical Center Corporation Treatment of severe distal colitis
US20130281504A1 (en) * 2010-06-28 2013-10-24 The Regents Of The University Of California Reduction of Microglia-Mediated Neurotoxicity by KCa3.1 Inhibition
WO2014159343A1 (en) * 2013-03-14 2014-10-02 Celtaxsys, Inc. Method of stimulating immune cell migration
US10343997B1 (en) 2018-12-04 2019-07-09 King Saud University Ursolic acid derivatives

Also Published As

Publication number Publication date
US20020119989A1 (en) 2002-08-29
AU1224599A (en) 1999-06-07
WO1999025347A2 (en) 1999-05-27
WO1999025347A3 (en) 1999-07-29
EP1052990A2 (en) 2000-11-22

Similar Documents

Publication Publication Date Title
US6545028B2 (en) Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction
JP3811726B2 (en) 1,2,3-triazole and imidazole compounds and their anti-tumor applications
US6624186B2 (en) Ion channel modulating agents comprising novel benzimidazolone derivatives
HU217621B (en) Process for the preparation of novel glyoxylyl pipecolic acid esters, their derivatives and pharmaceutical compositions containing them
EA006604B1 (en) Combination of serotonin agonist (5-ht) and antagonist (5-ht) as pharmaceutical formulation
CN104797578B (en) 6-((S)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1H-pyrazole-3 as a TARP-γ8-dependent AMPA receptor antagonist -yl}-ethyl)-3H-1,3-benzothiazol-2-one
US20240091210A1 (en) Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
CA2246027A1 (en) Benzylamidine derivatives with serotonin receptor binding activity
US20020065315A1 (en) Ion channel modulating agents
EP1167369A1 (en) Novel thiazolobenzimidazole derivatives
US9463187B2 (en) Methylphenidate derivatives and uses of them
US6525043B2 (en) Use of ion channel modulating agents
US6541492B1 (en) Thiazole derivatives as PPAR gamma ligands
US20010049447A1 (en) Mibefradil analogues and their use
US6797694B2 (en) Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction
AU2022233178A1 (en) Compositions and methods for treating polycythemia
US6759422B2 (en) Ion channel modulating agents
EP0885004B1 (en) Use of 4-phenyl-3,6-dihydro-2h-pyridyl derivatives as nmda receptor subtype blockers
EP0725776B1 (en) 3-aryl-4-alkyl and 4,5-dialkyl-4h-1,2,4-triazoles useful as memory enhancers
US5468763A (en) Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder
WO2003004010A1 (en) Carbonylamino derivatives useful for obtaining immune regulation
KR20010086355A (en) Vitronectin receptor antagonists
EA047194B1 (en) APPLICATION OF 5-[4-[2-[5-ACETYLPYRIDIN-2-YL]ETOXY]BENZYL]-1,3-THIAZOLIDINE-2,4-DIONE AND ITS SALTS
JP2024031105A (en) Fibrosis treatment or prevention drug
JPH09100418A (en) Benzothiazine derivative having fluorescence-expressing group

Legal Events

Date Code Title Description
AS Assignment

Owner name: NEUROSEARCH A/S, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JENSEN, BO S.;OLSEN, SOREN-PETER;JORGENSEN, TINO D.;AND OTHERS;REEL/FRAME:010964/0509;SIGNING DATES FROM 20000530 TO 20000614

AS Assignment

Owner name: NEUROSEARCH A/S, DENMARK

Free format text: CORRECTIVE ASSIGNMENT TO SECOND ASSIGNOR'S NAME AND ASSIGNEE'S ADDRESS CORRESPONDING TO THE ASSIGNMENT, PREVIOUSLY RECORDED AT REEL 010964, FRAME 0509;ASSIGNORS:JENSEN, BO S.;OLESEN, SOREN-PETER;JORGENSEN, TINO D.;AND OTHERS;REEL/FRAME:011271/0467;SIGNING DATES FROM 20000530 TO 20000614

AS Assignment

Owner name: POSEIDON PHARMACEUTICALS A/S, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NEUROSEARCH A/S;REEL/FRAME:013326/0107

Effective date: 20020917

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: NEUROSEARCH A/S, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:POSEIDON PHARMACEUTICALS A/S;REEL/FRAME:021064/0616

Effective date: 20080519

FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: ANIONA APS, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NEUROSEARCH A/S;REEL/FRAME:030049/0894

Effective date: 20130318

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20150408